<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000969.pub2" GROUP_ID="GYNAECA" ID="014399090210340139" MERGED_FROM="" MODIFIED="2017-03-08 11:32:39 +0000" MODIFIED_BY="Joanne Platt" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Short title (no longer in use): Amphotericin B lipid soluble vs amphotericin B&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-03-08 11:30:44 +0000" NOTES_MODIFIED_BY="Joanne Platt" REVIEW_NO="B022" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="15.0">
<COVER_SHEET MODIFIED="2017-03-08 11:32:37 +0000" MODIFIED_BY="Joanne Platt">
<TITLE>Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia</TITLE>
<CONTACT MODIFIED="2017-03-08 11:32:37 +0000" MODIFIED_BY="Joanne Platt"><PERSON ID="12436" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Helle Krogh</FIRST_NAME><LAST_NAME>Johansen</LAST_NAME><POSITION>Senior Researcher</POSITION><EMAIL_1>hkj@cochrane.dk</EMAIL_1><EMAIL_2>hkj@biosustain.dtu.dk</EMAIL_2><ADDRESS><DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK 2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 35 45 7112</PHONE_1><FAX_1>+45 35 45 70 07</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-03-08 11:32:37 +0000" MODIFIED_BY="Joanne Platt"><PERSON ID="12436" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Helle Krogh</FIRST_NAME><LAST_NAME>Johansen</LAST_NAME><POSITION>Senior Researcher</POSITION><EMAIL_1>hkj@cochrane.dk</EMAIL_1><EMAIL_2>hkj@biosustain.dtu.dk</EMAIL_2><ADDRESS><DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK 2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 35 45 7112</PHONE_1><FAX_1>+45 35 45 70 07</FAX_1></ADDRESS></PERSON><PERSON ID="6571" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Gøtzsche</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>pcg@cochrane.dk</EMAIL_1><URL>http://nordic.cochrane.org</URL><ADDRESS><DEPARTMENT>Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 7811</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3545 7112</PHONE_1><FAX_1>+45 3545 7007</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-03-08 11:29:40 +0000" MODIFIED_BY="Joanne Platt">
<UP_TO_DATE>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2017-03-08 11:30:44 +0000" MODIFIED_BY="Joanne Platt">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-03-08 11:30:44 +0000" MODIFIED_BY="Joanne Platt">
<DATE DAY="8" MONTH="3" YEAR="2017"/>
<DESCRIPTION>
<P>Intervention no longer in general use.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-09-21 14:18:40 +0100" MODIFIED_BY="Tracey Harrison">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-09-21 14:18:40 +0100" MODIFIED_BY="Tracey Harrison">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>One new trial added, conclusions not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-09-21 14:18:40 +0100" MODIFIED_BY="Tracey Harrison">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Literature searches re-run</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-27 11:23:42 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="14" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Review updated with new search details. No new studies were identified for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-03-27 11:23:42 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="18" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>Searches re-run in July 2011</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-15 11:34:36 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="5" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Minor update: Two new outcomes added in November 2007 (death ascribed to fungal infection and harms).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-15 11:36:22 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="5" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>New studies found and included or excluded: Two new outcomes added in (death ascribed to fungal infection and harms).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-07-10 15:43:29 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="30" MONTH="9" YEAR="2004"/>
<DESCRIPTION>
<P>New studies found and included or excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-15 11:39:26 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="3" MONTH="4" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Rigshospitalet</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>JASCHA-fonden</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Nordic Council of Ministers</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Swedish Society of Medicine</NAME>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-09-03 12:13:07 +0100" MODIFIED_BY="Clare Jess">
<SUMMARY MODIFIED="2014-09-03 12:07:17 +0100" MODIFIED_BY="Clare Jess">
<TITLE>Prevention of fungal infections in patients with cancer with amphotericin B</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-03 12:07:17 +0100" MODIFIED_BY="Clare Jess">
<P>Patients with cancer who are treated with chemotherapy or receive a bone marrow transplant have an increased risk of acquiring fungal infections. Such infections can be life-threatening. Antifungal drugs are therefore often given prophylactically to such patients, or when they have a fever. The review found that lipid formulations of amphotericin B had fewer adverse effects (less nephrotoxicity and fewer dropouts) than conventional amphotericin B. However, it is not clear whether there are any advantages of these formulations if conventional amphotericin B is administered under optimal circumstances.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-09-03 12:11:50 +0100" MODIFIED_BY="Clare Jess">
<ABS_BACKGROUND>
<P>Patients with cancer who are treated with chemotherapy or receive a bone marrow transplant have an increased risk of acquiring fungal infections. Such infections can be life-threatening. Antifungal drugs are therefore often given prophylactically to such patients, or when they have a fever. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare the benefits and harms of lipid soluble formulations of amphotericin B with conventional amphotericin B in cancer patients with neutropenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-09-03 12:07:05 +0100" MODIFIED_BY="Clare Jess">
<P>We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials comparing lipid soluble formulations of amphotericin B with conventional amphotericin B.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-09-03 12:07:07 +0100" MODIFIED_BY="Clare Jess">
<P>The two review authors independently assessed trial eligibility and risk of bias and abstracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-09-03 12:11:50 +0100" MODIFIED_BY="Clare Jess">
<P>We found 13 trials (1960 patients). Lipid-based amphotericin B was not more effective than conventional amphotericin B on mortality (relative risk (RR) 0.5; 95% confidence interval (CI) 0.64 to 1.14) but decreased invasive fungal infection (RR 0.65; 95% CI 0.44 to 0.97), nephrotoxicity defined as a 100% increase in serum creatinine (RR 0.45; 95% CI 0.37 to 0.54), and number of dropouts (RR 0.78; 95% CI 0.62 to 0.97).</P>
<P>For the drug used in most patients, AmBisome (4 trials, 1214 patients), there was no significant difference in mortality (RR 0.77; 95% CI 0.54 to 1.10) whereas it tended to be more effective than conventional amphotericin B on invasive fungal infection (RR 0.63; 95% CI 0.39 to 1.01, P value 0.053).</P>
<P>AmBisome, amphotericin B in Intralipid (6 trials, 379 patients), amphotericin B colloidal dispersion (ABCD) (2 trials, 262 patients), and amphotericin B lipid complex (ABLC) (1 trial, 105 patients) all decreased the occurrence of nephrotoxicity, but conventional amphotericin B was rarely administered under optimal circumstances.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-09-03 12:07:16 +0100" MODIFIED_BY="Clare Jess">
<P>It is not clear whether there are any advantages of lipid-based formulations if conventional amphotericin B is administered under optimal circumstances, and their high cost prohibits routine use in most settings. There is a need for large trials comparing lipid-based formulations of amphotericin B with conventional amphotericin B given in the same dose, with routine premedication for prevention of infusion-related toxicity, and with supplementation with fluid, potassium, and magnesium for prevention of nephrotoxicity.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-09-03 12:13:07 +0100" MODIFIED_BY="Clare Jess">
<BACKGROUND MODIFIED="2014-09-03 12:08:20 +0100" MODIFIED_BY="Clare Jess">
<P>Opportunistic fungal infections are a major cause of morbidity and mortality in neutropenic patients (<LINK REF="REF-Richardson-1998" TYPE="REFERENCE">Richardson 1998</LINK>). The mortality rate in patients with candidaemia or deep tissue infection is around 50% (<LINK REF="REF-Edwards-1997" TYPE="REFERENCE">Edwards 1997</LINK>). Therefore, some clinicians use antifungal agents prophylactically in patients undergoing antileukaemic chemotherapy or bone marrow transplantation, or empirically in patients with persistent fever of unknown origin where the effect is relatively modest. In a meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment we found that it was necessary to treat more than 50 patients to prevent one case of fungal invasion in patients who survived the neutropenic episode (<LINK REF="REF-G_x00f8_tzsche-1997" TYPE="REFERENCE">Gøtzsche 1997</LINK>; <LINK REF="REF-G_x00f8_tzsche-2002" TYPE="REFERENCE">Gøtzsche 2002</LINK>).</P>
<P>Amphotericin B has proven antimicrobial activity against Candida and Aspergillus species, which are the most prevalent fungal pathogens in cancer patients with neutropenia (<LINK REF="REF-Edwards-1997" TYPE="REFERENCE">Edwards 1997</LINK>). Lipid formulations of amphotericin B such as AmBisome, amphotericin B lipid complex (ABLC), or amphotericin B colloidal dispersion (ABCD) are sometimes preferred over conventional amphotericin B because of less nephrotoxicity (<LINK REF="REF-Richardson-1998" TYPE="REFERENCE">Richardson 1998</LINK>; <LINK REF="REF-Tang-1997" TYPE="REFERENCE">Tang 1997</LINK>). It is uncertain, however, how important this is, for example whether the use of such agents leads less often to renal failure. Furthermore, studies have shown that the nephrotoxicity of conventional amphotericin B can be reduced to a very low level by continuous infusion (<LINK REF="REF-Imhof-2003" TYPE="REFERENCE">Imhof 2003</LINK>) and by appropriate supplementation with fluid, potassium, and magnesium (<LINK REF="REF-Mayer-1999" TYPE="REFERENCE">Mayer 1999</LINK>; <LINK REF="STD-Nath-1999" TYPE="STUDY">Nath 1999</LINK>). For a proper assessment of the value of these drugs, it is also relevant to consider the considerable differences in cost. In some hospitals the costs for the new lipid formulations have accounted for a significant proportion of all expenditure on antimicrobial agents (<LINK REF="REF-Tang-1997" TYPE="REFERENCE">Tang 1997</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the benefits and harms of lipid soluble formulations of amphotericin B with conventional amphotericin B in cancer patients with neutropenia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-09-03 12:12:03 +0100" MODIFIED_BY="Clare Jess">
<SELECTION_CRITERIA MODIFIED="2014-09-03 12:08:22 +0100" MODIFIED_BY="Clare Jess">
<CRIT_STUDIES>
<P>All randomised trials, irrespective of language, which compared lipid soluble formulations of amphotericin B with conventional amphotericin B in cancer patients with neutropenia were eligible. Trials using quasi-randomisation methods were not accepted.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with cancer complicated by neutropenia caused by cancer chemotherapy or bone marrow transplantation.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-09-03 12:08:22 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: lipid soluble formulations of amphotericin B. Control: conventional amphotericin B. The drugs were given intravenously.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-09-03 12:08:22 +0100" MODIFIED_BY="Clare Jess">
<UL>
<LI>Mortality</LI>
<LI>Invasive fungal infection (defined as positive blood culture, oesophageal candidiasis, lung infection, or microscopically confirmed deep tissue involvement)</LI>
<LI>Nephrotoxicity (defined as a doubling of serum creatinine)</LI>
<LI>Other harms</LI>
<LI>Serum creatinine (µmol/l)</LI>
<LI>Dropouts</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-09-03 12:08:23 +0100" MODIFIED_BY="Clare Jess">
<P>We searched PubMed (from 1966 to 18 July 2011).<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-09-03 12:08:23 +0100" MODIFIED_BY="Clare Jess">
<P>We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified articles.</P>
<P>The search strategy used is in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. </P>
<P>The search strategies have been developed and executed by the authors.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-09-03 12:08:23 +0100" MODIFIED_BY="Clare Jess">
<P>This has not been carried out since 2007 as we have not found it worthwhile.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-03 12:12:03 +0100" MODIFIED_BY="Clare Jess">
<DATA_EXTRACTION MODIFIED="2014-09-03 12:08:26 +0100" MODIFIED_BY="Clare Jess">
<P>Decisions on which trials to include and which variables to use when a number of options were available for the same outcome were based on the methods sections of the trials only. Details on diagnosis, drug, dose, randomisation and blinding methods, number of randomised patients, number of patients excluded from the analysis, deaths, invasive fungal infections, nephrotoxicity, serum creatinine, and number of dropouts were extracted by both authors independently. When baseline and breakthrough fungal infections were reported separately, we combined the data. Differences in the data extracted were resolved by consensus.</P>
<P>We defined invasive fungal infection as a positive blood culture, oesophageal candidiasis, lung infection, or microscopically confirmed deep tissue infection (<LINK REF="REF-G_x00f8_tzsche-1997" TYPE="REFERENCE">Gøtzsche 1997</LINK>). We excluded cases of oropharyngeal and vulvovaginal candidiasis, skin infections, Candida in the urine, and vaguely described infections. The authors were contacted for supplementary information on their trials.<BR/>
</P>
</DATA_EXTRACTION>
<DATA_SYNTHESIS MODIFIED="2014-09-03 12:12:03 +0100" MODIFIED_BY="Clare Jess">
<P>The outcomes were weighted by the inverse variance; 95% CIs are presented. A fixed-effect model analysis was used unless P value was less than 0.10 for the test of heterogeneity.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-09-03 12:13:07 +0100" MODIFIED_BY="Clare Jess">
<STUDY_DESCRIPTION MODIFIED="2014-09-03 12:08:35 +0100" MODIFIED_BY="Clare Jess">
<P>We identified 13 relevant trials. Conventional amphotericin B was compared with AmBisome (Fugisome) in four trials (<LINK REF="STD-Jadhav-2012" TYPE="STUDY">Jadhav 2012</LINK>; <LINK REF="STD-Leenders-1998" TYPE="STUDY">Leenders 1998</LINK>; <LINK REF="STD-Prentice-1997" TYPE="STUDY">Prentice 1997</LINK>; <LINK REF="STD-Walsh-1999" TYPE="STUDY">Walsh 1999</LINK>), with amphotericin B in Intralipid in six trials (<LINK REF="STD-Caillot-1994" TYPE="STUDY">Caillot 1994</LINK>; <LINK REF="STD-Moreau-1992" TYPE="STUDY">Moreau 1992</LINK>; <LINK REF="STD-Nath-1999" TYPE="STUDY">Nath 1999</LINK>; <LINK REF="STD-Nucci-1999" TYPE="STUDY">Nucci 1999</LINK>; <LINK REF="STD-Pascual-1995" TYPE="STUDY">Pascual 1995</LINK>; <LINK REF="STD-Sch_x00f6_ffski-1998" TYPE="STUDY">Schöffski 1998</LINK>), with amphotericin B colloidal dispersion (ABCD) in two trials (<LINK REF="STD-Sandler-2000" TYPE="STUDY">Sandler 2000</LINK>; <LINK REF="STD-White-1998" TYPE="STUDY">White 1998</LINK>), and with amphotericin B lipid complex (ABLC) in one trial (<LINK REF="STD-Subira-2004" TYPE="STUDY">Subira 2004</LINK>). The trial drugs were given as an intravenous infusion. Premedication to prevent infusion-related toxicity was allowed in the AmBisome trials but in one of them only after the first day (<LINK REF="STD-Jadhav-2012" TYPE="STUDY">Jadhav 2012</LINK>) and in another only after the first dose (<LINK REF="STD-Walsh-1999" TYPE="STUDY">Walsh 1999</LINK>). For other lipid formulations premedication was routine in four studies (<LINK REF="STD-Moreau-1992" TYPE="STUDY">Moreau 1992</LINK>; <LINK REF="STD-Nath-1999" TYPE="STUDY">Nath 1999</LINK>; <LINK REF="STD-Subira-2004" TYPE="STUDY">Subira 2004</LINK>; <LINK REF="STD-White-1998" TYPE="STUDY">White 1998</LINK>), was only used in the control group (<LINK REF="STD-Nucci-1999" TYPE="STUDY">Nucci 1999</LINK>), according to the investigator's preference (<LINK REF="STD-Sandler-2000" TYPE="STUDY">Sandler 2000</LINK>), or not at all in three studies (<LINK REF="STD-Caillot-1994" TYPE="STUDY">Caillot 1994</LINK>; <LINK REF="STD-Pascual-1995" TYPE="STUDY">Pascual 1995</LINK>; <LINK REF="STD-Sch_x00f6_ffski-1998" TYPE="STUDY">Schöffski 1998</LINK>).</P>
<P>The drugs were given empirically in 11 trials, mainly empirically in one trial (<LINK REF="STD-Nucci-1999" TYPE="STUDY">Nucci 1999</LINK>), and in an intended treatment trial (<LINK REF="STD-Leenders-1998" TYPE="STUDY">Leenders 1998</LINK>). In the intended treatment trial, 109 patients were randomised but 43 were subsequently excluded, 40 of them according to the protocol as a suspected infection could not be confirmed. However, as this criterion applied to only 26 of the remaining 66 patients we included data from all 109 patients whenever possible.</P>
<P>Acute leukaemia was the most common disease in 11 trials; two trials were in patients who had undergone bone marrow or stem cell transplantation (<LINK REF="STD-Sandler-2000" TYPE="STUDY">Sandler 2000</LINK>; <LINK REF="STD-White-1998" TYPE="STUDY">White 1998</LINK>). Two studies included children as well as adults (<LINK REF="STD-Jadhav-2012" TYPE="STUDY">Jadhav 2012</LINK>; <LINK REF="STD-Prentice-1997" TYPE="STUDY">Prentice 1997</LINK>) and two only children (<LINK REF="STD-Nath-1999" TYPE="STUDY">Nath 1999</LINK>; <LINK REF="STD-Sandler-2000" TYPE="STUDY">Sandler 2000</LINK>). The doses were 1 to 5 mg/kg/day of AmBisome, 0.7 to 4.0 mg/kg/day of amphotericin B in Intralipid, 4.0 mg/kg/day of ABCD, 1 mg/kg/day of ABLC, and 0.6 to 1 mg/kg/day of conventional amphotericin B.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-03 12:09:11 +0100" MODIFIED_BY="Clare Jess">
<P>We adopted broad quality assessment criteria and considered the randomisation method to be concealed if central randomisation, sealed envelopes, or a code provided by a pharmacy or a company was described. Treatment allocation was adequately concealed in seven trials (<LINK REF="STD-Caillot-1994" TYPE="STUDY">Caillot 1994</LINK>; <LINK REF="STD-Jadhav-2012" TYPE="STUDY">Jadhav 2012</LINK>; <LINK REF="STD-Leenders-1998" TYPE="STUDY">Leenders 1998</LINK>; <LINK REF="STD-Nath-1999" TYPE="STUDY">Nath 1999</LINK>; <LINK REF="STD-Prentice-1997" TYPE="STUDY">Prentice 1997</LINK>; <LINK REF="STD-Subira-2004" TYPE="STUDY">Subira 2004</LINK>; <LINK REF="STD-Walsh-1999" TYPE="STUDY">Walsh 1999</LINK>) and blinding of the drugs was reported for three trials (<LINK REF="STD-Sandler-2000" TYPE="STUDY">Sandler 2000</LINK>; <LINK REF="STD-Walsh-1999" TYPE="STUDY">Walsh 1999</LINK>; <LINK REF="STD-White-1998" TYPE="STUDY">White 1998</LINK>). Few patients were excluded from analysis apart from the intended treatment trial (see above) (<LINK REF="STD-Leenders-1998" TYPE="STUDY">Leenders 1998</LINK>).</P>
<P>The length of the follow-up period was not always reported, and it sometimes varied for different patients within the same study since some authors stated that the follow-up ended one week after the last dose of trial drug (see the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>').</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-09-03 12:13:07 +0100" MODIFIED_BY="Clare Jess">
<P>We included 13 trials (1960 patients). Supplementation with potassium to prevent nephrotoxicity was used in only one of the trials (<LINK REF="STD-Nath-1999" TYPE="STUDY">Nath 1999</LINK>). Lipid-based amphotericin B was not more effective than conventional amphotericin B on mortality (RR 0.85; 95% CI 0.64 to 1.14) but decreased invasive fungal infection (RR 0.65; 95% CI 0.44 to 0.97), nephrotoxicity defined as a 100% increase in serum creatinine (RR 0.45; 95% CI 0.37 to 0.54), and number of dropouts (RR 0.78; 95% CI 0.62 to 0.97). There were only 12 deaths ascribed to fungal infection (RR 0.56; 95% CI 0.29 to 1.09).</P>
<SUBSECTION>
<HEADING LEVEL="3">AmBisome versus conventional amphotericin B (4 trials, 1214 patients)</HEADING>
<P>There was no significant difference in mortality (RR 0.77; 95% CI 0.54 to 1.10) whereas AmBisome tended to be more effective than conventional amphotericin B on invasive fungal infection (RR 0.63; 95% CI 0.39 to 1.01, P value 0.053) and decreased significantly the incidence of nephrotoxicity defined as a 100% increase in serum creatinine (RR 0.51; 95% CI 0.40 to 0.64). None of the trials reported on serum creatinine values. Fewer patients dropped out on AmBisome but the difference was not significant (RR 0.78; 95% CI 0.56 to 1.08). There were fewer infusion-related reactions to AmBisome (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amphotericin B in Intralipid versus conventional amphotericin B (6 trials, 379 patients)</HEADING>
<P>There were no significant differences in clinical effect whereas the patients treated with the lipid soluble formulation experienced significantly less nephrotoxicity (RR 0.44; 95% CI 0.24 to 0.81) and smaller increases in serum creatinine (weighted mean difference 19 µmol/l, 95% CI 5 to 34 µmol/l). In one of the studies (<LINK REF="STD-Sch_x00f6_ffski-1998" TYPE="STUDY">Schöffski 1998</LINK>), nephrotoxicity was not defined as a 100% increase in serum creatinine but as the numbers of patients with severe renal dysfunction. Two studies reported on renal dysfunction after therapy. In one, two patients in the lipid formulated amphotericin B group and one patient in the amphotericin B group underwent haemodialysis (<LINK REF="STD-Sch_x00f6_ffski-1998" TYPE="STUDY">Schöffski 1998</LINK>); in the other, one patient had a high serum creatinine (250 µmol/l) eight months after amphotericin B therapy (<LINK REF="STD-Moreau-1992" TYPE="STUDY">Moreau 1992</LINK>). There were fewer infusion-related reactions with the lipid formulation but more cases of severe dyspnoea (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amphotericin B colloidal dispersion (ABCD) versus conventional amphotericin B (2 trials, 262 patients)</HEADING>
<P>There were no significant differences in clinical effect whereas the patients treated with ABCD experienced significantly less nephrotoxicity (RR 0.35; 0.23 to 0.53). There were more infusion-related reactions and more cases of hypoxic events with ABCD (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amphotericin B lipid complex (ABLC) versus conventional amphotericin B (1 trial, 105 patients)</HEADING>
<P>There were no significant differences in clinical effect whereas the patients treated with ABLC experienced significantly less nephrotoxicity (RR 0.25; 95% CI 0.09 to 0.70) and fewer dropouts (RR 0.21; 95% CI 0.05 to 0.89). There was a tendency for fewer infusion-related reactions with ABLC (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-09-03 12:10:28 +0100" MODIFIED_BY="Clare Jess">
<P>All of the four different lipid soluble formulations of amphotericin B were associated with less nephrotoxicity than conventional amphotericin B. These results were seen even though the dose of AmBisome was two to five times higher than that for conventional amphotericin B, and for a trial in which the dose of ABCD was five times higher (<LINK REF="STD-Sandler-2000" TYPE="STUDY">Sandler 2000</LINK>). The studies were generally small, and it could therefore not be ascertained with certainty whether the higher doses of the individual drugs also led to better clinical effect, although the summary estimate suggested that this might be the case at least for some of them. We reported only on nephrotoxicity but AmBisome was also better tolerated with respect to other well-known adverse effects of amphotericin B. For example, in the only double-blind trial that compared the two drugs, the percentage of patients with an adverse reaction after the first infusion was 17% versus 44% for infusion-related fever and 18% versus 54% for chills (<LINK REF="STD-Walsh-1999" TYPE="STUDY">Walsh 1999</LINK>). The clinical importance of these differences is less clear, however. Premedication for prevention of infusion-related toxicity was not permitted before the first infusion and when all infusions were considered together 38% versus 74% of the patients had chills (<LINK REF="STD-Walsh-1999" TYPE="STUDY">Walsh 1999</LINK>). Thus, after the first infusion an additional 20% of the patients had chills in both groups, which suggests that the occurrence of chills might have been more similar if premedication had been allowed before all infusions. The relevance of equating a doubling in serum creatinine with nephrotoxicity is also not clear, and conventional amphotericin B was rarely given under optimal conditions (see below). It may be necessary to reduce the dosage of drugs which are excreted by the kidneys but no cases of renal failure were reported in the AmBisome trials and the nephrotoxicity seems to be reversible.</P>
<P>The authors of one of the Intralipid studies reported that pulmonary events, such as acute respiratory distress, were significantly more common in the Intralipid group and suggested that this could be due to fat overload or chemical incompatibility (<LINK REF="STD-Sch_x00f6_ffski-1998" TYPE="STUDY">Schöffski 1998</LINK>). This observation is in the opposite direction to that of the biggest AmBisome study (<LINK REF="STD-Walsh-1999" TYPE="STUDY">Walsh 1999</LINK>) where hypoxia occurred significantly less often (1 versus 22 cases) among patients receiving AmBisome. The clinical relevance of this finding is doubtful, however, as the hypoxia was predominantly diagnosed by pulse oximetry and not by clinical symptoms. The two published trials with ABCD reported more chills and fever, and in one more clinical hypoxia, on this drug than on conventional amphotericin B (<LINK REF="STD-Sandler-2000" TYPE="STUDY">Sandler 2000</LINK>; <LINK REF="STD-White-1998" TYPE="STUDY">White 1998</LINK>). Another multicentre trial of ABCD was stopped prematurely by the company despite objections from the investigators; data from one of the centres showed no differences in clinical effect, nephrotoxicity, or chills (<LINK REF="STD-Winston-1999" TYPE="STUDY">Winston 1999</LINK>). We excluded a fourth trial of ABCD as only 50% of the patients had cancer. This trial had considerable statistical power as it was a treatment trial in 231 patients with haematogenous and invasive candidiasis but it has only been published as an abstract (<LINK REF="STD-Anaissie-1995" TYPE="STUDY">Anaissie 1995</LINK>). There were no differences in clinical effect or adverse effects apart from less nephrotoxicity with ABCD. In the ABLC study there was no difference in infusion-related adverse events; one patient in the conventional amphotericin B group required haemodialysis (<LINK REF="STD-Subira-2004" TYPE="STUDY">Subira 2004</LINK>).</P>
<P>Amphotericin B is an old drug but because of its broad antimycotic activity it is still widely regarded as the drug of choice for treatment of life-threatening mycoses (<LINK REF="REF-Viscoli-1997" TYPE="REFERENCE">Viscoli 1997</LINK>), and as empirical therapy in febrile patients with neutropenia (<LINK REF="REF-Hughes-1997" TYPE="REFERENCE">Hughes 1997</LINK>). The present meta-analysis, like the previous ones, renders support for this practice. In a meta-analysis of the placebo controlled trials of antifungal agents, intravenous amphotericin B was the only antifungal agent that reduced total mortality (<LINK REF="REF-G_x00f8_tzsche-1997" TYPE="REFERENCE">Gøtzsche 1997</LINK>; <LINK REF="REF-G_x00f8_tzsche-2002" TYPE="REFERENCE">Gøtzsche 2002</LINK>). It should be noted, however, that most of the trials were small, both in our review of the placebo controlled trials and in the present review. Survival estimates in small trials in cancer patients are often biased (<LINK REF="REF-Berlin-1989" TYPE="REFERENCE">Berlin 1989</LINK>); furthermore, bias in reporting of mortality differences can occur when trials have no formal stopping rules or when the length of follow-up was not determined in advance. One of the AmBisome trials illustrates the importance of length of follow-up (<LINK REF="STD-Leenders-1998" TYPE="STUDY">Leenders 1998</LINK>). An unpublished company trial report noted 5 versus 6 deaths during the study and 21 versus 19 deaths in total among its 109 patients. The published version of this trial is more favourable for AmBisome than the company report as it notes 7 versus 13 deaths based on a subsample of only 66 patients. Because of the uncertainty, we included the lowest number of deaths in our analysis as we did not find it reasonable to give this trial the same weight as the two larger AmBisome trials. Taken together, the results of the present review and those of the review of the placebo controlled trials show that amphotericin B decreases mortality. It would be interesting to analyse the numbers of deaths after extended follow-up, for example one and three months after randomisation, for all the studies that compare higher doses of amphotericin B with lower doses, preferably in an individual patient data meta-analysis. The study by Walsh, for example, reported the number of deaths after only seven days, despite the fact that many of the patients were neutropenic and therefore at risk of dying from a fungal infection, and under treatment with trial drug for much longer. The median follow-up in the placebo controlled trials of antifungal agents was much longer (<LINK REF="REF-G_x00f8_tzsche-1997" TYPE="REFERENCE">Gøtzsche 1997</LINK>; <LINK REF="REF-G_x00f8_tzsche-2002" TYPE="REFERENCE">Gøtzsche 2002</LINK>) and in the three other AmBisome trials it was 30 days (<LINK REF="STD-Prentice-1997" TYPE="STUDY">Prentice 1997</LINK>), 42 days (<LINK REF="STD-Leenders-1998" TYPE="STUDY">Leenders 1998</LINK>), and 49 days (<LINK REF="STD-Jadhav-2012" TYPE="STUDY">Jadhav 2012</LINK>), respectively.</P>
<P>The studies we reviewed indicate that some lipid soluble formulations of amphotericin B may be better drugs than conventional amphotericin B but there are two important caveats. First, is the benefit worth the extra cost? The high costs prohibit routine use in most settings. Second, it is not clear whether there are any advantages of AmBisome if conventional amphotericin B is administered under optimal circumstances. We noted above that one of the large trials of AmBisome did not use effective premedication and the drugs seem not to have been infused slowly. Infusion-related toxicity could possibly be reduced by infusing conventional amphotericin B over 4 hours (<LINK REF="REF-Ellis-1992" TYPE="REFERENCE">Ellis 1992</LINK>), and further reduced if the infusion-time is 24 hours (<LINK REF="REF-Eriksson-2001" TYPE="REFERENCE">Eriksson 2001</LINK>; <LINK REF="REF-Imhof-2003" TYPE="REFERENCE">Imhof 2003</LINK>). It is also important to supplement the therapy with fluid, potassium, and magnesium to prevent nephrotoxicity. It is remarkable that in a study where 32 patients received sufficient substitution to cover the losses induced by a mean dose of amphotericin B of 0.9 mg/kg/d over 20 days no increase in serum creatinine was observed (<LINK REF="REF-Mayer-1999" TYPE="REFERENCE">Mayer 1999</LINK>). And in one of the trials in the present review, where potassium supplementation was used, only one patient out of 78 on conventional amphotericin B experienced a doubling of serum creatinine (<LINK REF="STD-Nath-1999" TYPE="STUDY">Nath 1999</LINK>). Furthermore, the chosen doses in the reviewed trials can be discussed. Conventional amphotericin B has been given in similarly high doses as those used for AmBisome (2 to 5 mg/kg/d) (<LINK REF="REF-Hiddemann-1991" TYPE="REFERENCE">Hiddemann 1991</LINK>), and the trial by Walsh et al (<LINK REF="STD-Walsh-1999" TYPE="STUDY">Walsh 1999</LINK>) has been criticised for using only 0.6 mg/kg/d of conventional amphotericin B (<LINK REF="REF-Fischer-1999" TYPE="REFERENCE">Fischer 1999</LINK>). Conversely, it is possible that AmBisome could be given in smaller doses than those used in the trials we reviewed without loss of effect. In one of the studies we included in our review (<LINK REF="STD-Prentice-1997" TYPE="STUDY">Prentice 1997</LINK>) the patients on AmBisome were randomised to 1 or 3 mg/kg/d (118 patients in both groups) and there was a similar clinical effect. In an EORTC study of patients with invasive Aspergillosis, a partial or complete clinical response was obtained in 26 patients randomised to 1 mg AmBisome and in 22 patients receiving 4 mg (<LINK REF="REF-Ellis-1998" TYPE="REFERENCE">Ellis 1998</LINK>). In a third study of Aspergillosis, the clinical effect was similar for AmBisome 3 mg/kg/d (107 patients) as for 10 mg/kg/d (94 patients) (<LINK REF="REF-Cornely-2007" TYPE="REFERENCE">Cornely 2007</LINK>). It would be interesting to compare lipid formulations of amphotericin B with conventional amphotericin B in the same doses and with optimal conditions for the use of amphotericin B.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-09-03 12:10:31 +0100" MODIFIED_BY="Clare Jess">
<IMPLICATIONS_PRACTICE MODIFIED="2014-09-03 12:10:31 +0100" MODIFIED_BY="Clare Jess">
<P>Some lipid soluble formulations of amphotericin B may be better drugs than conventional amphotericin B but their high cost prohibits routine use in most settings. Furthermore, it is not clear whether there are any advantages of these formulations if conventional amphotericin B is administered under optimal circumstances.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-09-03 12:10:31 +0100" MODIFIED_BY="Clare Jess">
<P>There is a need for large trials comparing lipid formulations of amphotericin B with conventional amphotericin B given in the same dose, with routine premedication for prevention of infusion-related toxicity, and with supplementation with fluid, potassium, and magnesium for prevention of nephrotoxicity.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-09-03 12:10:32 +0100" MODIFIED_BY="Clare Jess">
<P>The review is funded in part by a grant from the European Association of Neuro-Oncology.</P>
<P>We wish to thank our funders for the research grants which made this review possible. We also thank Dr Denis Caillot, Dr Alexander CA Leenders, Dr Marcio Nucci and Dr C Nath for additional information on their trials and Dr Karsten Witt, Nextar, for excerpts from the company trial report for Leenders' study.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Gynaecological Cancer Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS, or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-07-23 13:16:01 +0100" MODIFIED_BY="Tracey Bishop">
<P>Helle Krogh Johansen - nothing to declare<BR/>Peter C Gøtzsche - nothing to declare</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-09-03 12:10:33 +0100" MODIFIED_BY="Clare Jess">
<P>HKJ wrote the draft meta-analysis protocol, HKJ and PCG contributed equally to selection of trials, data extraction, and writing of the manuscript. Guarantors: both authors.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-09-03 12:10:34 +0100" MODIFIED_BY="Clare Jess">
<P>Need for additional antifungal treatment was dropped because it was rarely reported; we have reported on dropouts instead and added harms. Also, we have added death ascribed to fungal infection as our research has shown that this outcome is reliable, contrary to our expectations (<LINK REF="REF-Due-2006" TYPE="REFERENCE">Due 2006</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-03-08 11:32:39 +0000" MODIFIED_BY="Joanne Platt">
<STUDIES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<INCLUDED_STUDIES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="MIX" ID="STD-Caillot-1994" MODIFIED="2014-07-31 15:13:26 +0100" MODIFIED_BY="Clare Jess" NAME="Caillot 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-07-31 15:13:26 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B</AU>
<TI>A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1994</YR>
<VL>33</VL>
<NO>3</NO>
<PG>603-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347867"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347866"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jadhav-2012" MODIFIED="2014-07-31 15:13:32 +0100" MODIFIED_BY="Clare Jess" NAME="Jadhav 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-31 15:13:32 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jadhav MP, Shinde VM, Chandrakala S et al</AU>
<TI>A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India</TI>
<SO>Indian Journal of Cancer</SO>
<YR>2012</YR>
<VL>49</VL>
<PG>107-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347869"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347868"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Leenders-1998" MODIFIED="2014-07-31 15:12:16 +0100" MODIFIED_BY="Clare Jess" NAME="Leenders 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-07-31 15:12:16 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW</AU>
<TI>Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections</TI>
<SO>British Journal of Haematology</SO>
<YR>1998</YR>
<VL>103</VL>
<NO>1</NO>
<PG>205-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347871"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-10 16:11:02 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Leenders ACAP, Daenen S, Jansen R, Hop WCJ, Löwenberg B, Wijermans PW et al</AU>
<TI>Ambisome compared with amphotericin B deoxycholate in the treatment of neutropenia-associated invasive fungal infections</TI>
<SO>The Tenth International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, 21-24 June 1998. International Immunocompromised Host Society</SO>
<YR>1998</YR>
<PG>Abstract 100</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347872"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-29 10:19:46 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Leenders ACAP, Daenen S, Jansen RHL, Hop WCJ, L&amp;#246;wenberg B, Cornelissen J, Herbrecht R, de Marie S. Liposomal amphotericin B (AmBisome) compared with amphotericin B in the treatment of neutropenia-associated invasive fungal infections.Trends in Invasive Fungal Infections 4, November 5-8, 1997, Barcelona, Spain: P-4.&lt;/p&gt;" NOTES_MODIFIED="2011-09-29 10:19:46 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Leenders ACAP, Daenen S, Jansen RHL, Hop WCJ, Löwenberg B, Cornelissen J et al</AU>
<TI>Liposomal amphotericin B (AmBisome) compared with amphotericin B in the treatment of neutropenia-associated invasive fungal infections</TI>
<SO>Trends in Invasive Fungal Infections 4. Final Programme and Abstract Book, November 5-8, 1997, Barcelona, Spain</SO>
<YR>1997</YR>
<PG>54 (P-6)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347873"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Leenders ACAP, Daenen S, Schouten H, Lelie J, Herbrecht R, Hop WCJ, Hoogsteden HC, Verbrugh HA, de Marie S. AmBisome 5 mg/kg versus conventional amphotericin B (AmB) 1 mg/kg in the treatment of neutropenia associated invasive aspergillosis. Clin Microbiol Infect 1997; 3 Suppl 2: 336 (P1356).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leenders ACAP, Daenen S, Schouten H, Lelie J, Herbrecht R, Hop WCJ et al</AU>
<TI>AmBisome 5 mg/kg versus conventional amphotericin B (AmB) 1 mg/kg in the treatment of neutropenia associated invasive aspergillosis</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>1997</YR>
<VL>3 Suppl 2</VL>
<PG>336 (P1356)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347874"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347870"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreau-1992" MODIFIED="2014-07-31 15:13:11 +0100" MODIFIED_BY="Clare Jess" NAME="Moreau 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Moreau P, Milpied N Fayette N Ram&amp;#218;e JF Casassus P and Harousseau JL. Amphotericin B mixed with IntralipidR: reduction of nephrotoxicity in neutropenic patients. Proc-Annu-Meet-Am-Soc-Clin-Oncol 1992.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Moreau P, Milpied N, Fayette N, Ramée JF, Casassus P, Harousseau JL</AU>
<TI>Amphotericin B mixed with IntralipidR: reduction of nephrotoxicity in neutropenic patients</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1992</YR>
<VL>11</VL>
<PG>380 (abstract 1319)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347876"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:13:11 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL</AU>
<TI>Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients [see comments]</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>4</NO>
<PG>535-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347877"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347875"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nath-1999" MODIFIED="2014-07-31 15:13:43 +0100" MODIFIED_BY="Clare Jess" NAME="Nath 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-31 15:13:43 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother 1999; 43(6):1417-23.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:13:43 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW</AU>
<TI>Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>6</NO>
<PG>1417-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347879"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347878"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nucci-1999" MODIFIED="2014-07-31 15:14:01 +0100" MODIFIED_BY="Clare Jess" NAME="Nucci 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-31 15:14:01 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Nucci M, Loureiro M, Silveira F, Casali AR, Bouzas LF, Velasco E et al. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob Agents Chemother 1999; 43(6):1445-8.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:14:01 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nucci M, Loureiro M, Silveira F, Casali AR, Bouzas LF, Velasco E</AU>
<TI>Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>6</NO>
<PG>1445-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347881"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347880"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pascual-1995" MODIFIED="2014-07-31 15:14:14 +0100" MODIFIED_BY="Clare Jess" NAME="Pascual 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-07-31 15:14:14 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pascual B, Ayestaran A, Montoro JB, Oliveras J, Estibalez A, Julia A</AU>
<TI>Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1995</YR>
<VL>29</VL>
<NO>12</NO>
<PG>1197-201</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347883"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347882"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prentice-1997" MODIFIED="2014-07-31 15:14:18 +0100" MODIFIED_BY="Clare Jess" NAME="Prentice 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-07-31 15:14:18 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D</AU>
<TI>A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients</TI>
<SO>British Journal of Haematology</SO>
<YR>1997</YR>
<VL>98</VL>
<NO>3</NO>
<PG>711-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347885"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347884"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandler-2000" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NAME="Sandler 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Sandler ES, Mustafa MM, Tkaczewski I, Graham ML, Morrison VA, Green M et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 2000; 22(3):242-6.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:10:55 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sandler ES, Mustafa MM, Tkaczewski I, Graham ML, Morrison VA, Green M</AU>
<TI>Use of amphotericin B colloidal dispersion in children</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>3</NO>
<PG>242-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347887"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347886"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sch_x00f6_ffski-1998" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NAME="Schöffski 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Sch&amp;#246;ffski P, Freund M, Wunder R, Petersen D, Ganser A. No evidence of improved toxicity of amphotericin B in intralipid: results of a confirmatory randomized phase II-trial. Clin Microbiol Infect 1997; 3 Suppl 2: 305 (P1237).&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:10:55 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schöffski P, Freund M, Wunder R, Petersen D, Ganser A</AU>
<TI>No evidence of improved toxicity of amphotericin B in intralipid: results of a confirmatory randomized phase II-trial</TI>
<SO>Clinical Microbiology and Infection. Abstracts of 8th European Congress of Clinical Microbiology and Infectious Diseases. May 25-28, 1997, Lausanne, Switzerland.</SO>
<YR>1997</YR>
<VL>3 Suppl 2</VL>
<PG>305 (P1237)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347889"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:15:15 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schoffski P, Freund M, Wunder R, Petersen D, Kohne CH, Hecker H</AU>
<TI>Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<NO>7155</NO>
<PG>379-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347890"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347888"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subira-2004" MODIFIED="2014-07-31 15:15:23 +0100" MODIFIED_BY="Clare Jess" NAME="Subira 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-07-31 15:15:23 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial. Eur J Haematol 2004; 72(5):342-7.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:15:23 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J</AU>
<TI>Low-dose amphotericin B lipid complex versus conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial</TI>
<SO>European Journal of Haematology</SO>
<YR>2004</YR>
<VL>72</VL>
<NO>5</NO>
<PG>342-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347892"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347891"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-1999" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NAME="Walsh 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Cagnoni PJ, . = Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18:2476-83.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN</AU>
<TI>Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>2476-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347894"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002; 49 Suppl 1:81-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cagnoni PJ</AU>
<TI>Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2002</YR>
<VL>49 Suppl 1</VL>
<PG>81-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347895"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Walsh T, Bodensteiner D, Hiemenz J, Thaler S, Greenberg R, Arndt C et al. A randomized, double-blind trial of ambisome (liposomal amphotericin B) versus Amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Ann Hematol 1999; 78 Suppl 1:S3.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:10:55 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh T, Bodensteiner D, Hiemenz J, Thaler S, Greenberg R, Arndt C</AU>
<TI>A randomized, double-blind trial of ambisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients</TI>
<SO>Annals of Hematology</SO>
<YR>1999</YR>
<VL>78 Suppl 1</VL>
<PG>S3 (abstract 10)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347896"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Walsh TJ, Bodensteiner D, Hiemenz J, Thaler S, Greenberg RN, Arndt C et al The mycoses study group (MSG) and the empirical antifungal study group</AU>
<TI>A randomised, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients</TI>
<SO>Abstracts in Clinical Trials of Antimicrobials &amp; Unique and Instructive Clinical Observations. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997, September 28-October 1, Toronto, Canada.</SO>
<PG>381 (Poster LM-90)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347897"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:15:52 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D</AU>
<TI>Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>10</NO>
<PG>764-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347898"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347893"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1998" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NAME="White 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR</AU>
<TI>Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>2</NO>
<PG>296-302</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347900"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347899"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="PUB" ID="STD-Anaissie-1995" NAME="Anaissie 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Anaissie EJ, White M, Uzun O</AU>
<TI>Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invesive candidiasis: a prospective, randomized, multicenter trial</TI>
<SO>35th Interscience Conference on Antimicrobial Agents and Chemotherapy</SO>
<YR>1995</YR>
<PG>330 (LM21)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347902"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347901"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowden-2002" NAME="Bowden 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bowden R, Chandrasekar P, White M, van Burik J-A, Wingard J. The Multicenter Aspergillus Study Group</AU>
<TI>A double-blind, randomized controlled trial of Amphocil (ABCD) versus amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients</TI>
<SO>The Tenth International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, 21-24 June 1998. International Immunocompromised Host Society</SO>
<YR>1998</YR>
<PG>Abstract 091</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347904"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35(4):359-66.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M et al</AU>
<TI>A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>4</NO>
<PG>359-66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347905"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347903"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richard-1999" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NAME="Richard 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Richard J</AU>
<TI>Ambisome treatment for empiric treatment of fungal infections in haematology</TI>
<SO>Trends in invasive fungal infections 5, Malta, 14-16 October</SO>
<YR>1999</YR>
<PG>128 (P6.08)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347907"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347906"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uhlenbrock-2001" NAME="Uhlenbrock 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Uhlenbrock S, Zimmermann M, Fegeler W, Jurgens H, Ritter J. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study. Mycoses 2001; 44(11-12):455-63.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uhlenbrock S, Zimmermann M, Fegeler W, Jurgens H, Ritter J</AU>
<TI>Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study</TI>
<SO>Mycoses</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>11-12</NO>
<PG>455-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347909"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347908"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Winston-1999" NAME="Winston 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winston DW, Schiller GJ, Territo MC</AU>
<TI>Liposomal amphotericin B for fever and neutropenia (letter)</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>1154</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347911"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347910"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zoubeck-1992" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NAME="Zoubeck 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zoubek A, Emminger W, Emminger Schmidmeier W, Peters C, Pracher E, Grois N</AU>
<TI>Conventional versus liposomal amphotericin B in immunosuppressed children [letter]</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>1992</YR>
<VL>9</VL>
<NO>2</NO>
<PG>187-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3347913"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3347912"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<ADDITIONAL_REFERENCES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<REFERENCE ID="REF-Berlin-1989" NAME="Berlin 1989" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JA, Begg CB, Louis TA</AU>
<TI>An assessment of publication bias using a sample of published clinical trials</TI>
<SO>Journal of the American Statistical Association</SO>
<YR>1989</YR>
<VL>84</VL>
<PG>381-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cornely-2007" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NAME="Cornely 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E et al</AU>
<TI>Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>44(10)</VL>
<PG>1289-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Due-2006" MODIFIED="2008-08-07 12:29:14 +0100" MODIFIED_BY="[Empty name]" NAME="Due 2006" TYPE="JOURNAL_ARTICLE">
<AU>Due AK, Johansen HK, Gøtzsche PC</AU>
<TI>Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-1997" NAME="Edwards 1997" TYPE="JOURNAL_ARTICLE">
<AU>Edwards JE, Bodey GB, Bowden RA, Büchner T, de Pauw BE, Filler SG</AU>
<TI>International conference for the development of a consensus on the management and prevention of severe candidal infections</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>43-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-1992" NAME="Ellis 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ellis ME, al-Hokail AA, Clink HM, Padmos MA, Ernst P, Spence DG</AU>
<TI>Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1992</YR>
<VL>36</VL>
<PG>172-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-1998" NAME="Ellis 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ellis M, Spence D, de Pauw B</AU>
<TI>An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1998</YR>
<VL>27</VL>
<PG>1406-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eriksson-2001" NAME="Eriksson 2001" NOTES="&lt;p&gt;Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322(7286):579-82.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson U, Seifert B, Schaffner A</AU>
<TI>Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>322</VL>
<NO>7286</NO>
<PG>579-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fischer-1999" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NAME="Fischer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fischer T, Heubel G, Huber C</AU>
<TI>Liposomal amphotericin B for fever and neutropenia (letter)</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>1152</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1997" NAME="Gøtzsche 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<PG>1238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2002" MODIFIED="2011-09-29 11:11:58 +0100" MODIFIED_BY="Clare Jess" NAME="Gøtzsche 2002" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Routine versus selective antifungal administration for control of fungal infections in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:11:53 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:11:53 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000026"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hiddemann-1991" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NAME="Hiddemann 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hiddemann W, Essink ME, Fegeler W, Zuhlsdorf M, Sauerland C, Buchner T</AU>
<TI>Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia</TI>
<SO>Cancer</SO>
<YR>1991</YR>
<VL>68</VL>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-1997" NAME="Hughes 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hughes WT, Armstrong D, Bodey GP</AU>
<TI>1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>551-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imhof-2003" NAME="Imhof 2003" TYPE="JOURNAL_ARTICLE">
<AU>Imhof A, Walter RB, Schaffner A</AU>
<TI>Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>36</VL>
<PG>943-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayer-1999" NAME="Mayer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mayer J, Doubek M, Vorlicek J</AU>
<TI>Must we really fear toxicity of conventional amphotericin B in oncological patients?</TI>
<SO>Support Care Cancer</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>1</NO>
<PG>51-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richardson-1998" NAME="Richardson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Richardson MD, Kokki MH</AU>
<TI>Antifungal therapy in "bone marrow failure"</TI>
<SO>British Journal of Haematology</SO>
<YR>1998</YR>
<VL>100</VL>
<PG>619-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-1997" NAME="Tang 1997" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tang CM, Bowler ICJW</AU>
<TI>Do the new lipid formulations of amphotericin B really work?</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>1997</YR>
<VL>3</VL>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Viscoli-1997" NAME="Viscoli 1997" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Viscoli C, Castagnola E, Machetti M</AU>
<TI>Antifungal treatment in patients with cancer</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1997</YR>
<VL>242 Suppl 740</VL>
<PG>89-94</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-09-29 11:14:14 +0100" MODIFIED_BY="Clare Jess">
<REFERENCE ID="REF-Johansen-2000" MODIFIED="2011-09-29 11:14:14 +0100" MODIFIED_BY="Clare Jess" NAME="Johansen 2000" TYPE="COCHRANE_REVIEW">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:14:09 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:14:09 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000969"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johansen-2002a" MODIFIED="2011-09-29 11:12:53 +0100" MODIFIED_BY="Clare Jess" NAME="Johansen 2002a" TYPE="COCHRANE_REVIEW">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:12:50 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:12:50 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000969"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-09-03 12:13:23 +0100" MODIFIED_BY="Clare Jess">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Caillot-1994">
<CHAR_METHODS MODIFIED="2014-09-03 12:10:35 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: random table, opaque envelopes<BR/>Blinding of study: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 09:49:28 +0100" MODIFIED_BY="Tracey Bishop">
<P>42 patients with AL<BR/>Excluded: NA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:37 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B + 20% intralipid 1.0 to 1.1 mg/kg/d as a 2 hour infusion<BR/>Control: amphotericin B same dose<BR/>Premedication to prevent infusion-related toxicity was not used<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:49:45 +0100" MODIFIED_BY="Tracey Bishop">
<P>Deaths<BR/>Infections<BR/>Dropouts<BR/>Nephrotoxicity<BR/>Serum creatinine<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 30<BR/>Days on amphotericin B + 20% intralipid: 12.8<BR/>Days on amphotericin B: 8.4<BR/>All got nystatin or fluconazole prophylactically</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Jadhav-2012">
<CHAR_METHODS MODIFIED="2014-07-24 15:06:55 +0100" MODIFIED_BY="Clare Jess">
<P>Computer generated central randomisation list, blocks of 6, sealed envelopes. No blinding</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 15:06:55 +0100" MODIFIED_BY="Clare Jess">
<P>65 patients with AL</P>
<P>Excluded: 8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: liposomal amphotericin B (Fungisome) at either 1 or 3 mg/kg/d as a 2 hour infusion (2 groups)<BR/>Control: amphotericin B 1 mg/kg/d<BR/>Premedication to prevent infusion-related toxicity was not used on the first day<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Primary outcome: "Investigator assessment of overall treatment success" (criteria for this were stated)</P>
<P>Fever resolution<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>This trial was heavily biased. A test dose of 1 ml was used for Fungisome but not for amphotericin B, no premedication was used for amphotericin B, and in one of the Fungisome groups, the dose was three times as large as for amphotericin B. The trial was seriously underpowered, with a one-sided alpha of 0.20 and beta also of 0.20. It was planned to randomise 150 patients, but only 65 were enrolled. There were no data on mycology</P>
<P>Follow-up period (days): 49<BR/>Days on Fungisome: 17<BR/>Days on amphotericin B: 15<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Leenders-1998">
<CHAR_METHODS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: sealed envelopes<BR/>Blinding of study: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>109 patients with neutropenia<BR/>Excluded: 43, 40 of which did not have fungal infection (20 were randomised to AmBisome, 20 to amphotericin B). We included those patients after obtaining information from the author and the company</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: AmBisome 5 mg/kg/d as infusion<BR/>Control: amphotericin B 1 mg/kg/d as infusion over 6 h; premedication to prevent infusion-related toxicity was allowed<BR/>Mainly empiric (only 26 patients had documented infection)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:50:27 +0100" MODIFIED_BY="Tracey Bishop">
<P>Deaths<BR/>Dropouts<BR/>Nephrotoxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 42<BR/>Days on AmBisome: 14.5<BR/>Days on amphotericin B: 16.5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Moreau-1992">
<CHAR_METHODS MODIFIED="2014-07-24 09:50:37 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: NA<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 09:50:35 +0100" MODIFIED_BY="Tracey Bishop">
<P>32 patients with AL<BR/>Excluded: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B + 20% Intralipid 0.7-1.0 mg/kg/d as a 4 hour infusion<BR/>Control: amphotericin B same dose<BR/>Premedication to prevent infusion-related toxicity was routine<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:50:43 +0100" MODIFIED_BY="Tracey Bishop">
<P>Infections<BR/>Nephrotoxicity<BR/>Serum creatinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): NA<BR/>Days on amphotericin B + 20% Intralipid: 18<BR/>Days on amphotericin B: 11</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Nath-1999">
<CHAR_METHODS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: consecutively numbered, sealed and opaque envelopes. Computer generated random numbers<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>130 children, mostly with AL (162 courses; 20 versus 12 patients were entered into the study a second time)<BR/>Excluded: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B + 20% intralipid 1.0 mg/kg/d as a 2 hour infusion<BR/>Control: amphotericin B, same dose<BR/>Premedication: hydrocortisone, 3 mg/kg<BR/>Potassium supplements were given to maintain serum level above 3 mmol/l. Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:51:22 +0100" MODIFIED_BY="Tracey Bishop">
<P>Deaths<BR/>Infections<BR/>Nephrotoxicity<BR/>Serum creatinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): NA<BR/>Days on amphotericin B + 20% Intralipid: 6.9<BR/>Days on amphotericin B: 6.3<BR/>Only two cases of nephrotoxicity (doubling of serum creatinine from baseline)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Nucci-1999">
<CHAR_METHODS MODIFIED="2014-07-24 09:51:29 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: sealed envelopes<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 09:51:31 +0100" MODIFIED_BY="Tracey Bishop">
<P>72 patients with AL<BR/>Excluded: 11</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B + 20% intralipid 1.0 mg/kg/d as a 1 hour infusion<BR/>Control: amphotericin B, same dose<BR/>Premedication only in control group: promethazine plus antipyretic<BR/>Empiric in 49 patients, treatment in 11 and secondary prophylaxis in one</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:51:39 +0100" MODIFIED_BY="Tracey Bishop">
<P>Infections<BR/>Nephrotoxicity<BR/>Serum creatinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period: one week after stop treatment<BR/>Days on amphotericin B + 20% Intralipid: 7.5<BR/>Days on amphotericin B: 9<BR/>Fungal invasive infections as defined by authors, not specified by species or location. Not clear how many infections there were at follow-up. Data not useable for our meta-analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Pascual-1995">
<CHAR_METHODS MODIFIED="2014-07-24 09:51:47 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: NA<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 09:51:49 +0100" MODIFIED_BY="Tracey Bishop">
<P>20 patients with AL<BR/>Excluded: NA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B + 20% Intralipid 1.0 mg/kg/d as a one hour infusion<BR/>Control: amphotericin B 0.1 mg/kg/d as a one hour infusion<BR/>Premedication to prevent infusion-related toxicity was not used<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:51:54 +0100" MODIFIED_BY="Tracey Bishop">
<P>Serum creatinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period: NA<BR/>Days on amphotericin B + 20% Intralipid: 7.0<BR/>Days on amphotericin B: 7.4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Prentice-1997">
<CHAR_METHODS MODIFIED="2014-07-24 09:52:07 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: central randomisation, blinded, numbered envelopes<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 09:52:08 +0100" MODIFIED_BY="Tracey Bishop">
<P>338 patients with AL (204 were children)<BR/>Excluded: 3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: AmBisome 1 mg/kg/d to 118 patients and 3 mg/kg/d to 118 patients, as infusion<BR/>Control: amphotericin B 1 mg/kg/d as infusion to 102 patients; gradual dose increase and premedication to prevent infusion-related toxicity was allowed<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:52:14 +0100" MODIFIED_BY="Tracey Bishop">
<P>Deaths<BR/>Infections<BR/>Nephrotoxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-09 08:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>Follow-up period (days): 30<BR/>Days on drugs: till neutrophil count above 0.5 x 10<SUP>9</SUP> /l for 3 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Sandler-2000">
<CHAR_METHODS MODIFIED="2014-07-24 09:52:21 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: NA<BR/>Blinding: double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 09:52:23 +0100" MODIFIED_BY="Tracey Bishop">
<P>49 children undergoing BMT<BR/>Excluded: 3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B colloidal dispersion (ABCD) 4 mg/kg/d as infusion<BR/>Control: amphotericin B 0.8 mg/kg/d as infusion<BR/>Premedication: according to investigator's preference<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:52:27 +0100" MODIFIED_BY="Tracey Bishop">
<P>Deaths<BR/>Infections<BR/>Nephrotoxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period: 7 days after last dose of trial drug<BR/>Days on ABCD: 9.6<BR/>Days on amphotericin B: 8.5<BR/>Sponsored by SEQUUS Pharmaceutical<BR/>No data on mortality: "No drug-related mortality was seen"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Sch_x00f6_ffski-1998">
<CHAR_METHODS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>51 patients with AL<BR/>Excluded: NA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B + 20% Intralipid 0.75 mg/kg/d as a 1-4 hour infusion<BR/>Control: amphotericin B 0.75 mg/kg/d as a 1-4 hour infusion<BR/>Premedication to prevent infusion-related toxicity was not used<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Deaths<BR/>Nephrotoxicity<BR/>Serum creatinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): NA<BR/>Days on amphotericin B + 20% Intralipid: 9.9<BR/>Days on amphotericin B: 11.3<BR/>Nephrotoxicity was not defined. Two patients on amphotericin B + Intralipid and one on amphotericin B underwent haemodialysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Subira-2004">
<CHAR_METHODS>
<P>Allocation concealment: blinded numbered envelopes, sequential opening<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 09:52:36 +0100" MODIFIED_BY="Tracey Bishop">
<P>105 patients with AL<BR/>Excluded: 9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B lipid complex (ABLC) 1 mg/kg/d as a 2 hour infusion. Control: amphotericin B 0.6 mg/kg/d as a 6 hour infusion. Premedication in all cases</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:52:42 +0100" MODIFIED_BY="Tracey Bishop">
<P>Deaths<BR/>Nephrotoxicity<BR/>Dropouts<BR/>Infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-24 09:52:45 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA. Days on amphotericin B lipid complex (ABLC): 8<BR/>Days on amphotericin B: 6</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Walsh-1999">
<CHAR_METHODS MODIFIED="2014-07-24 09:52:49 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: central randomisation<BR/>Blinding: double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 09:52:51 +0100" MODIFIED_BY="Tracey Bishop">
<P>702 patients with AL<BR/>Excluded: 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: AmBisome 3 mg/kg/d as infusion<BR/>Control: amphotericin B 0.6 mg/kg/d as infusion; premedication to prevent infusion-related toxicity was allowed after the first infusion<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Deaths<BR/>Infections<BR/>Dropouts<BR/>Nephrotoxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 7<BR/>Days on AmBisome: 10.8<BR/>Days on amphotericin B: 10.3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-White-1998">
<CHAR_METHODS MODIFIED="2014-07-24 09:52:59 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: NA<BR/>Blinding: double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-24 09:53:00 +0100" MODIFIED_BY="Tracey Bishop">
<P>213 patients undergoing BMT<BR/>Excluded: 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: Amphotec (ABCD, amphotericin B cholesteryl sulfate complex) 4.0 mg/kg/d as infusion<BR/>Control: amphotericin B 0.8 mg/kg/d as infusion<BR/>Premedication to prevent infusion-related toxicity was routine<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 09:53:07 +0100" MODIFIED_BY="Tracey Bishop">
<P>Deaths<BR/>Infections<BR/>Dropouts<BR/>Nephrotoxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 28<BR/>Days on Amphotec: 9<BR/>Days on amphotericin B: 7.5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AL: acute leukaemia<BR/>BMT: bone marrow transplantation<BR/>NA: not available</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-09-03 12:13:23 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:13:09 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Anaissie-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:13:09 +0100" MODIFIED_BY="Clare Jess">
<P>Only 50% of patients had cancer, unpublished trial. Treatment of invasive candidiasis, 153 patients received amphotericin B lipid complex (ABLC), 5 mg/kg/d, and 78 amphotericin B, 0.6 to 1.0 mg/kg/d. Response rates 63% versus 68%; more cases with doubling of baseline creatinine with conventional amphotericin B, 28% versus 47% (P value 0.007)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:13:23 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Bowden-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:13:23 +0100" MODIFIED_BY="Clare Jess">
<P>More than two-thirds of the patients did not have neutropenia. Trial of 174 patients that compared amphotericin B colloidal dispersion, 6 mg/kg/d, with amphotericin B, 1.0 to 1.5 mg/kg/d. Response rates 52% versus 51%; more cases with nephrotoxicity (doubling of baseline creatinine, and similar) with conventional amphotericin B, 25% versus 49% (P value 0.002)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-24 09:53:31 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Richard-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-24 09:53:31 +0100" MODIFIED_BY="Tracey Bishop">
<P>Published as an abstract, no useful data. Empiric treatment with AmBisome (N = 19) or amphotericin B (N = 11)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-24 09:53:32 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Uhlenbrock-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-24 09:53:32 +0100" MODIFIED_BY="Tracey Bishop">
<P>Only 14 of the patients were randomised. For the other 15 patients, treatment was assigned according to the wishes of the parents, patients or physicians</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-24 09:53:34 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Winston-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-24 09:53:34 +0100" MODIFIED_BY="Tracey Bishop">
<P>Multicentre trial that compared amphotericin B lipid complex (ABLC) with amphotericin B. Despite objections from the investigators, the trial was prematurely discontinued by the sponsor, the Liposome Company, Princeton, New Jersey. An analysis of the patients at the University of California, Los Angeles, showed no difference in clinical reponses or in nephrotoxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-24 09:53:36 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Zoubeck-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-24 09:53:36 +0100" MODIFIED_BY="Tracey Bishop">
<P>Not an RCT (personnal communication with first author)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-07-24 15:06:59 +0100" MODIFIED_BY="Clare Jess">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-07-24 15:06:59 +0100" MODIFIED_BY="Clare Jess" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Caillot-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-24 15:06:59 +0100" MODIFIED_BY="Clare Jess" RESULT="YES" STUDY_ID="STD-Jadhav-2012">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Leenders-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Moreau-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nath-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nucci-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pascual-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Prentice-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sandler-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Subira-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Walsh-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-White-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-07-24 15:06:59 +0100" MODIFIED_BY="Clare Jess" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:08:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caillot-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-07-24 15:06:59 +0100" MODIFIED_BY="Clare Jess" RESULT="NO" STUDY_ID="STD-Jadhav-2012">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:09:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leenders-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:09:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moreau-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:09:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nath-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:09:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nucci-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:09:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pascual-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:10:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prentice-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:10:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sandler-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:10:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sch_x00f6_ffski-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:10:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Subira-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:10:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walsh-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:11:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-09-03 12:10:55 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE>Harms</TITLE>
<TABLE COLS="5" ROWS="13">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Experimental drug</P>
</TH>
<TH>
<P>Control drug</P>
</TH>
<TH>
<P>Number of patients</P>
</TH>
<TH>
<P>Harms</P>
</TH>
</TR>
<TR>
<TD>
<P>Leenders 1998</P>
</TD>
<TD>
<P>AmBisome</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>52 versus 54</P>
</TD>
<TD>
<P>Chills/fever: 5 versus 12; Other acute reactions: 5 versus 3; Other clinical events and laboratory values similar</P>
</TD>
</TR>
<TR>
<TD>
<P>Prentice 1997</P>
</TD>
<TD>
<P>AmBisome</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>236 versus 102</P>
</TD>
<TD>
<P>Severe test-drug-related side-effects: 3 (encephalopathy, convulsions, hypokalaemia) versus 11 (7 renal toxicity, 2 rigors, rash and fever, 1 hypokalaemia, 1 dyspnoea); Clinical adverse events: 40% versus 64%</P>
</TD>
</TR>
<TR>
<TD>
<P>Walsh 1999</P>
</TD>
<TD>
<P>AmBisome</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>343 versus 344</P>
</TD>
<TD>
<P>Chills or rigors: 63 versus 187; Fever: 58 versus 150; Nausea: 42 versus 35; Vomiting: 21 versus 28; Hypotension: 12 versus 28</P>
</TD>
</TR>
<TR>
<TD>
<P>Caillot 1994</P>
</TD>
<TD>
<P>Amphotericin B + 20% Intralipid</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>21 versus 21</P>
</TD>
<TD>
<P>Chills: 5 versus 16</P>
</TD>
</TR>
<TR>
<TD>
<P>Moreau 1992</P>
</TD>
<TD>
<P>Amphotericin B + 20% Intralipid</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>16 versus 16</P>
</TD>
<TD>
<P>Rigors and fever: 5 versus 12</P>
</TD>
</TR>
<TR>
<TD>
<P>Nath 1999</P>
</TD>
<TD>
<P>Amphotericin B + 20% Intralipid</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>84 versus 78</P>
</TD>
<TD>
<P>Rigors or fever, or both: 21 versus 19</P>
</TD>
</TR>
<TR>
<TD>
<P>Nucci 1999</P>
</TD>
<TD>
<P>Amphotericin B + 20% Intralipid</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>28 versus 33</P>
</TD>
<TD>
<P>Fever: 19 versus 28; Rigors: 6% versus 33% of administrations; Hypotension: 1 versus 3</P>
</TD>
</TR>
<TR>
<TD>
<P>Pascual 1995</P>
</TD>
<TD>
<P>Amphotericin B + 20% Intralipid</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>10 versus 10</P>
</TD>
<TD>
<P>Fever: 3 versus 5; Chills: 7 versus 8; Nausea: 3 versus 4<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Schöffski 1998</P>
</TD>
<TD>
<P>Amphotericin B + 20% Intralipid</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>27 versus 24</P>
</TD>
<TD>
<P>Severe dyspnoea: 11 versus 4 (see Discussion); Other harms: very detailed presentation, only minor differences</P>
</TD>
</TR>
<TR>
<TD>
<P>Sandler 2000</P>
</TD>
<TD>
<P>ABCD</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>25 versus 21</P>
</TD>
<TD>
<P>Data not reliable, eg 50.0% of 21 patients had chills on amphotericin B, which is 11.5 patients</P>
</TD>
</TR>
<TR>
<TD>
<P>White 1998</P>
</TD>
<TD>
<P>ABCD</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>109 versus 104</P>
</TD>
<TD>
<P>Chills: 87 versus 68; Hypoxic events: 16 versus 3</P>
</TD>
</TR>
<TR>
<TD>
<P>Subira 2004</P>
</TD>
<TD>
<P>ABLC</P>
</TD>
<TD>
<P>Amphotericin B</P>
</TD>
<TD>
<P>49 versus 56</P>
</TD>
<TD>
<P>Chills/rigors: 31 versus 33; Fever: 27 versus 37; Nausea/vomiting: 4 versus 7</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-07-24 09:54:53 +0100" MODIFIED_BY="Tracey Bishop">
<COMPARISON ID="CMP-001" MODIFIED="2014-07-24 09:54:53 +0100" MODIFIED_BY="Tracey Bishop" NO="1">
<NAME>Lipid-based amphotericin B versus standard amphotericin B</NAME>
<DICH_OUTCOME CHI2="3.743548563977505" CI_END="1.1351519785057698" CI_START="0.6364985521507985" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8500132885961471" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.05505401043471899" LOG_CI_START="-0.1962025799029165" LOG_EFFECT_SIZE="-0.07057428473409874" METHOD="MH" MODIFIED="2014-07-13 12:19:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8794885640773366" P_Q="0.4081654588259458" P_Z="0.2708748379524667" Q="2.894584686505891" RANDOM="NO" SCALE="21.692000797693037" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="953" TOTAL_2="789" WEIGHT="100.00000000000003" Z="1.1010501744661239">
<NAME>Death</NAME>
<GROUP_LABEL_1>Lipid-based</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lipid-based</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7227236526095524" CI_END="1.097263124733801" CI_START="0.539933754265096" DF="3" EFFECT_SIZE="0.7697073459141283" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="57" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.040310784290650666" LOG_CI_START="-0.26765952151404104" LOG_EFFECT_SIZE="-0.11367436861169519" MODIFIED="2014-07-13 12:19:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8678465703686271" P_Z="0.14793120789445893" STUDIES="4" TAU2="0.0" TOTAL_1="677" TOTAL_2="521" WEIGHT="71.13450311449002" Z="1.4468775998524133">
<NAME>AmBisome</NAME>
<DICH_DATA CI_END="6.042505130098826" CI_START="0.2942120427705291" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.78121702779672" LOG_CI_START="-0.5313395545801202" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2014-07-13 12:19:24 +0100" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="0.7710022337480251" STUDY_ID="STD-Jadhav-2012" TOTAL_1="45" TOTAL_2="20" VAR="0.5944444444444443" WEIGHT="3.138770284857483"/>
<DICH_DATA CI_END="2.664401924203038" CI_START="0.2806799620027261" EFFECT_SIZE="0.8647798742138365" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.42559973862784034" LOG_CI_START="-0.5517885909361803" LOG_EFFECT_SIZE="-0.06309442615417002" ORDER="1" O_E="0.0" SE="0.5741227429361657" STUDY_ID="STD-Leenders-1998" TOTAL_1="53" TOTAL_2="55" VAR="0.3296169239565466" WEIGHT="6.674730636625945"/>
<DICH_DATA CI_END="1.503776429578" CI_START="0.42337854205593695" EFFECT_SIZE="0.7979139504563233" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.17718327334475323" LOG_CI_START="-0.3732711569515928" LOG_EFFECT_SIZE="-0.09804394180341978" ORDER="2" O_E="0.0" SE="0.3233396571494485" STUDY_ID="STD-Prentice-1997" TOTAL_1="236" TOTAL_2="102" VAR="0.1045485338855229" WEIGHT="20.576382978510168"/>
<DICH_DATA CI_END="1.134417642478748" CI_START="0.42759310036191217" EFFECT_SIZE="0.6964690638160026" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="36" LOG_CI_END="0.054772972045256337" LOG_CI_START="-0.3689693111782364" LOG_EFFECT_SIZE="-0.15709816956649003" ORDER="3" O_E="0.0" SE="0.2489083147236106" STUDY_ID="STD-Walsh-1999" TOTAL_1="343" TOTAL_2="344" VAR="0.06195534913854799" WEIGHT="40.74461921449642"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12001153193901441" CI_END="1.5908335000536304" CI_START="0.23388474925960615" DF="2" EFFECT_SIZE="0.6099767981438515" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.2016247278603644" LOG_CI_START="-0.6309980959691021" LOG_EFFECT_SIZE="-0.21468668405436886" NO="2" P_CHI2="0.9417591095814406" P_Z="0.3121459925162624" STUDIES="3" TAU2="0.0" TOTAL_1="132" TOTAL_2="123" WEIGHT="10.643022213783876" Z="1.0107293642795314">
<NAME>Intralipid</NAME>
<DICH_DATA CI_END="5.103130184031393" CI_START="0.04898953994595213" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.707836647596448" LOG_CI_START="-1.3098966389244104" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="4" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-Caillot-1994" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="2.266889650174849"/>
<DICH_DATA CI_END="14.592576882122193" CI_START="0.05908791195169554" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.16413199010236" LOG_CI_START="-1.2285013568451622" LOG_EFFECT_SIZE="-0.03218468337140124" ORDER="5" O_E="0.0" SE="1.4054446717230549" STUDY_ID="STD-Nath-1999" TOTAL_1="84" TOTAL_2="78" VAR="1.9752747252747254" WEIGHT="1.1754242630536254"/>
<DICH_DATA CI_END="1.8518196067075514" CI_START="0.18963293158990097" EFFECT_SIZE="0.5925925925925926" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.26759867801154524" LOG_CI_START="-0.7220862410176703" LOG_EFFECT_SIZE="-0.22724378150306254" ORDER="6" O_E="0.0" SE="0.5813458204571208" STUDY_ID="STD-Sch_x00f6_ffski-1998" TOTAL_1="27" TOTAL_2="24" VAR="0.3379629629629629" WEIGHT="7.2007083005554025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.343842618163404" CI_START="0.6073232020094438" DF="0" EFFECT_SIZE="1.1930926216640503" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.3699284467838165" LOG_CI_START="-0.2165801268929346" LOG_EFFECT_SIZE="0.07667415994544094" NO="3" P_CHI2="1.0" P_Z="0.6083350746632521" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="95" WEIGHT="14.963820799599782" Z="0.5124514756735766">
<NAME>ABCD</NAME>
<DICH_DATA CI_END="2.343842618163404" CI_START="0.6073232020094438" EFFECT_SIZE="1.1930926216640503" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.3699284467838165" LOG_CI_START="-0.2165801268929346" LOG_EFFECT_SIZE="0.07667415994544094" ORDER="7" O_E="0.0" SE="0.3445180394419865" STUDY_ID="STD-White-1998" TOTAL_1="98" TOTAL_2="95" VAR="0.11869267950095017" WEIGHT="14.963820799599782"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0029371031148625E-31" CI_END="7.159298866933925" CI_START="0.4584071173691826" DF="0" EFFECT_SIZE="1.811594202898551" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" ID="CMP-001.01.04" LOG_CI_END="0.8548704925408958" LOG_CI_START="-0.33874864799929344" LOG_EFFECT_SIZE="0.2580609222708012" NO="4" P_CHI2="0.0" P_Z="0.39672209437991135" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="50" WEIGHT="3.2586538721263456" Z="0.8474899510057425">
<NAME>ABLC</NAME>
<DICH_DATA CI_END="7.159298866933925" CI_START="0.45840711736918255" EFFECT_SIZE="1.8115942028985508" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8548704925408958" LOG_CI_START="-0.3387486479992935" LOG_EFFECT_SIZE="0.25806092227080113" ORDER="8" O_E="0.0" SE="0.701137791663344" STUDY_ID="STD-Subira-2004" TOTAL_1="46" TOTAL_2="50" VAR="0.4915942028985507" WEIGHT="3.2586538721263456"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.569775397603345" CI_END="1.0890363850804476" CI_START="0.29048351969380626" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5624474395112736" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="0.0" I2_Q="15.499597882980346" ID="CMP-001.02" LOG_CI_END="0.03704238992628609" LOG_CI_START="-0.5368785018590813" LOG_EFFECT_SIZE="-0.24991805596639757" METHOD="MH" MODIFIED="2008-07-10 16:03:15 +0100" MODIFIED_BY="Clare Jess" NO="2" P_CHI2="0.4628130053155952" P_Q="0.30622775884403985" P_Z="0.08782923731507958" Q="2.3668526419913567" RANDOM="NO" SCALE="146.5253845360764" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="651" TOTAL_2="646" WEIGHT="100.00000000000001" Z="1.7069613453402204">
<NAME>Death ascribed to fungal infection</NAME>
<GROUP_LABEL_1>Lipid-based</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lipid-based</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.25095822974002613" CI_END="0.9242833640328388" CI_START="0.2121250726473278" DF="1" EFFECT_SIZE="0.4427907810040566" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="21" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.034194863661177494" LOG_CI_START="-0.6734079959396623" LOG_EFFECT_SIZE="-0.35380142980041995" NO="1" P_CHI2="0.6164011996455054" P_Z="0.030032499060645826" STUDIES="2" TAU2="0.0" TOTAL_1="375" TOTAL_2="378" WEIGHT="93.05350036110056" Z="2.1696614949565536">
<NAME>AmBisome</NAME>
<DICH_DATA CI_END="1.3858796743301625" CI_START="0.20364434786620894" EFFECT_SIZE="0.53125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.1417255253386231" LOG_CI_START="-0.6911276392218872" LOG_EFFECT_SIZE="-0.27470105694163205" ORDER="9" O_E="0.0" SE="0.4892220715524982" STUDY_ID="STD-Leenders-1998" TOTAL_1="32" TOTAL_2="34" VAR="0.23933823529411768" WEIGHT="43.63129459107949"/>
<DICH_DATA CI_END="1.1341326710895931" CI_START="0.11727336747969401" EFFECT_SIZE="0.3646965279618341" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.054663861392765176" LOG_CI_START="-0.9308006039957714" LOG_EFFECT_SIZE="-0.438068371301503" ORDER="10" O_E="0.0" SE="0.5788667050970034" STUDY_ID="STD-Walsh-1999" TOTAL_1="343" TOTAL_2="344" VAR="0.33508666226986117" WEIGHT="49.422205770021066"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="88.60546520032729" CI_START="0.22492796458679282" DF="0" EFFECT_SIZE="4.464285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="1.94746051007152" LOG_CI_START="-0.6479565467398456" LOG_EFFECT_SIZE="0.6497519816658373" NO="2" P_CHI2="1.0" P_Z="0.326426181562542" STUDIES="3" TAU2="0.0" TOTAL_1="132" TOTAL_2="123" WEIGHT="2.3770823232404155" Z="0.9813378390239405">
<NAME>Intralipid</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" O_E="0.0" SE="0.0" STUDY_ID="STD-Caillot-1994" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" O_E="0.0" SE="0.0" STUDY_ID="STD-Nath-1999" TOTAL_1="84" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="88.60546520032729" CI_START="0.22492796458679282" EFFECT_SIZE="4.464285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.94746051007152" LOG_CI_START="-0.6479565467398456" LOG_EFFECT_SIZE="0.6497519816658373" ORDER="13" O_E="0.0" SE="1.5245608266926296" STUDY_ID="STD-Sch_x00f6_ffski-1998" TOTAL_1="27" TOTAL_2="24" VAR="2.3242857142857143" WEIGHT="2.3770823232404155"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.276481279447559" CI_START="0.061513682539318174" DF="0" EFFECT_SIZE="0.9693877551020408" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="1.1840233321911857" LOG_CI_START="-1.2110282729984798" LOG_EFFECT_SIZE="-0.013502470403647106" NO="3" P_CHI2="1.0" P_Z="0.98236882897227" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="95" WEIGHT="4.569417315659037" Z="0.022099194552737508">
<NAME>ABCD</NAME>
<DICH_DATA CI_END="15.276481279447566" CI_START="0.061513682539318146" EFFECT_SIZE="0.9693877551020408" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.184023332191186" LOG_CI_START="-1.21102827299848" LOG_EFFECT_SIZE="-0.013502470403647106" ORDER="14" O_E="0.0" SE="1.4068651685850615" STUDY_ID="STD-White-1998" TOTAL_1="98" TOTAL_2="95" VAR="1.9792696025778733" WEIGHT="4.569417315659037"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>ABLC</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15" O_E="0.0" SE="0.0" STUDY_ID="STD-Subira-2004" TOTAL_1="46" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.991946770734843" CI_END="0.9683603572839352" CI_START="0.43609926010123784" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6498470861078739" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.013962998004815756" LOG_CI_START="-0.36041465016267116" LOG_EFFECT_SIZE="-0.18718882408374346" METHOD="MH" MODIFIED="2008-07-10 16:05:16 +0100" MODIFIED_BY="Clare Jess" NO="3" P_CHI2="0.6481341398881392" P_Q="0.5306308623333552" P_Z="0.03417944169787792" Q="2.2066954749871166" RANDOM="NO" SCALE="32.99605011828745" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="924" TOTAL_2="787" WEIGHT="100.0" Z="2.1179483557225254">
<NAME>Invasive fungal infection</NAME>
<GROUP_LABEL_1>Lipid-based</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3277553333902072" CI_END="1.0083651656320172" CI_START="0.3898883809066401" DF="2" EFFECT_SIZE="0.62701663597621" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="40" I2="14.08031714883262" ID="CMP-001.03.01" LOG_CI_END="0.0036178343912584548" LOG_CI_START="-0.40905970706212946" LOG_EFFECT_SIZE="-0.2027209363354355" NO="1" P_CHI2="0.3122729857030243" P_Z="0.05415446153512379" STUDIES="3" TAU2="0.0" TOTAL_1="631" TOTAL_2="500" WEIGHT="71.70834638027173" Z="1.9255990172393183">
<NAME>AmBisome</NAME>
<DICH_DATA CI_END="1.691989210864064" CI_START="0.35851371123765496" EFFECT_SIZE="0.7788461538461539" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.22839758939027377" LOG_CI_START="-0.44549423023053497" LOG_EFFECT_SIZE="-0.1085483204201306" ORDER="16" O_E="0.0" SE="0.3958473906635696" STUDY_ID="STD-Leenders-1998" TOTAL_1="52" TOTAL_2="54" VAR="0.15669515669515668" WEIGHT="20.831301853462058"/>
<DICH_DATA CI_END="7.157169290100957" CI_START="0.3197209807349349" EFFECT_SIZE="1.5127118644067796" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.8547412897984282" LOG_CI_START="-0.495228863514255" LOG_EFFECT_SIZE="0.17975621314208662" ORDER="17" O_E="0.0" SE="0.7929791505159024" STUDY_ID="STD-Prentice-1997" TOTAL_1="236" TOTAL_2="102" VAR="0.6288159331529222" WEIGHT="4.941547632815648"/>
<DICH_DATA CI_END="0.9022909105791171" CI_START="0.23746404358350373" EFFECT_SIZE="0.4628840547207894" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="26" LOG_CI_END="-0.04465341756885347" LOG_CI_START="-0.6244021412200136" LOG_EFFECT_SIZE="-0.3345277793944335" ORDER="18" O_E="0.0" SE="0.3405472700751571" STUDY_ID="STD-Walsh-1999" TOTAL_1="343" TOTAL_2="344" VAR="0.11597244315564201" WEIGHT="45.93549689399403"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.35165675995645607" CI_END="1.219702918017414" CI_START="0.18457447596646198" DF="2" EFFECT_SIZE="0.4744744744744745" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.0862540628245769" LOG_CI_START="-0.7338283559283714" LOG_EFFECT_SIZE="-0.3237871465518972" NO="2" P_CHI2="0.8387619546307542" P_Z="0.12170020151121072" STUDIES="3" TAU2="0.0" TOTAL_1="121" TOTAL_2="115" WEIGHT="21.821678918076444" Z="1.547676505158414">
<NAME>Intralipid</NAME>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" ORDER="19" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-Caillot-1994" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="1.7693253176818737"/>
<DICH_DATA CI_END="4.978428653813436" CI_START="0.050216648140272525" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6970922876062648" LOG_CI_START="-1.2991522789342274" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="20" O_E="0.0" SE="1.1726039399558574" STUDY_ID="STD-Moreau-1992" TOTAL_1="16" TOTAL_2="16" VAR="1.375" WEIGHT="3.5386506353637475"/>
<DICH_DATA CI_END="1.2862319708385352" CI_START="0.13241777821208442" EFFECT_SIZE="0.4126984126984127" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.10931930029121728" LOG_CI_START="-0.8780537032567447" LOG_EFFECT_SIZE="-0.38436720148276377" ORDER="21" O_E="0.0" SE="0.5799877898592662" STUDY_ID="STD-Nath-1999" TOTAL_1="84" TOTAL_2="78" VAR="0.33638583638583636" WEIGHT="16.513702965030824"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.378849435174659" CI_END="5.16288133010569" CI_START="0.2846364053936875" DF="1" EFFECT_SIZE="1.2122474925836983" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="27.47576533812556" ID="CMP-001.03.03" LOG_CI_END="0.7128921428135282" LOG_CI_START="-0.5457095538285298" LOG_EFFECT_SIZE="0.08359129449249922" NO="3" P_CHI2="0.2402974197351032" P_Z="0.7945969322399618" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="116" WEIGHT="5.643187170024773" Z="0.26034594910128145">
<NAME>ABCD</NAME>
<DICH_DATA CI_END="4.313682171770555" CI_START="0.040893137921562836" EFFECT_SIZE="0.42" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6348481435177739" LOG_CI_START="-1.3883495627219729" LOG_EFFECT_SIZE="-0.37675070960209955" ORDER="22" O_E="0.0" SE="1.1884363476353927" STUDY_ID="STD-Sandler-2000" TOTAL_1="25" TOTAL_2="21" VAR="1.4123809523809523" WEIGHT="3.846359386264943"/>
<DICH_DATA CI_END="27.468244190609294" CI_START="0.3078978590326988" EFFECT_SIZE="2.9081632653061225" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4388308995843622" LOG_CI_START="-0.5115933309523315" LOG_EFFECT_SIZE="0.46361878431601533" ORDER="23" O_E="0.0" SE="1.145688847772905" STUDY_ID="STD-White-1998" TOTAL_1="98" TOTAL_2="95" VAR="1.3126029359112066" WEIGHT="1.7968277837598303"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.875294925163389E-32" CI_END="82.07536217205335" CI_START="0.14250805223961127" DF="0" EFFECT_SIZE="3.4199999999999995" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="100.0" ID="CMP-001.03.04" LOG_CI_END="1.9142128078068268" LOG_CI_START="-0.846160595694557" LOG_EFFECT_SIZE="0.534026106056135" NO="4" P_CHI2="0.0" P_Z="0.44823830128755315" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="56" WEIGHT="0.8267875316270438" Z="0.7583553249328844">
<NAME>ABLC</NAME>
<DICH_DATA CI_END="82.07536217205335" CI_START="0.14250805223961133" EFFECT_SIZE="3.42" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9142128078068268" LOG_CI_START="-0.8461605956945568" LOG_EFFECT_SIZE="0.534026106056135" ORDER="24" O_E="0.0" SE="1.6214570012854315" STUDY_ID="STD-Subira-2004" TOTAL_1="49" TOTAL_2="56" VAR="2.6291228070175436" WEIGHT="0.8267875316270438"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.799129783043826" CI_END="0.5396800519592898" CI_START="0.37198244326308016" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.44805301506424733" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="264" I2="15.247987064514717" I2_Q="18.607074583337575" ID="CMP-001.04" LOG_CI_END="-0.26786363434188876" LOG_CI_START="-0.4294775573597645" LOG_EFFECT_SIZE="-0.34867059585082666" METHOD="MH" MODIFIED="2008-07-10 16:05:03 +0100" MODIFIED_BY="Clare Jess" NO="4" P_CHI2="0.298725046620959" P_Q="0.29744916868472615" P_Z="2.7442143443388228E-17" Q="3.685824025420583" RANDOM="NO" SCALE="33.80962394237473" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="956" TOTAL_2="826" WEIGHT="100.0" Z="8.456967043119839">
<NAME>Nephrotoxicity</NAME>
<GROUP_LABEL_1>Lipid-based</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.829925587106806" CI_END="0.6372189182577493" CI_START="0.4030189353385829" DF="2" EFFECT_SIZE="0.50676551778297" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="156" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.1957113390024447" LOG_CI_START="-0.3946745485986653" LOG_EFFECT_SIZE="-0.295192943800555" NO="1" P_CHI2="0.4005315776375684" P_Z="6.033580182609919E-9" STUDIES="3" TAU2="0.0" TOTAL_1="617" TOTAL_2="493" WEIGHT="60.37958806416971" Z="5.815824337711469">
<NAME>AmBisome</NAME>
<DICH_DATA CI_END="0.7681801672500184" CI_START="0.12126981506381412" EFFECT_SIZE="0.3052164261931188" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="-0.11453690957004184" LOG_CI_START="-0.9162472847275587" LOG_EFFECT_SIZE="-0.5153920971488003" ORDER="25" O_E="0.0" SE="0.47092864289788605" STUDY_ID="STD-Leenders-1998" TOTAL_1="53" TOTAL_2="55" VAR="0.22177378670164466" WEIGHT="6.113529801722436"/>
<DICH_DATA CI_END="0.7454119909344215" CI_START="0.26426618582492667" EFFECT_SIZE="0.4438323824513083" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="-0.12760362532679098" LOG_CI_START="-0.5779584034560068" LOG_EFFECT_SIZE="-0.35278101439139886" ORDER="26" O_E="0.0" SE="0.2645406259652067" STUDY_ID="STD-Prentice-1997" TOTAL_1="221" TOTAL_2="94" VAR="0.0699817427860634" WEIGHT="11.824983788991966"/>
<DICH_DATA CI_END="0.7219745060401404" CI_START="0.4240828914426648" EFFECT_SIZE="0.5533326631145069" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="116" LOG_CI_END="-0.14147813772339238" LOG_CI_START="-0.37254924770515097" LOG_EFFECT_SIZE="-0.25701369271427166" ORDER="27" O_E="0.0" SE="0.13573231382372672" STUDY_ID="STD-Walsh-1999" TOTAL_1="343" TOTAL_2="344" VAR="0.018423261015942632" WEIGHT="42.44107447345531"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.628570998979319" CI_END="0.8097775778464736" CI_START="0.236812633503676" DF="4" EFFECT_SIZE="0.43791044833624543" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" I2="28.934004728280815" ID="CMP-001.04.02" LOG_CI_END="-0.09163425270018652" LOG_CI_START="-0.6255951325463327" LOG_EFFECT_SIZE="-0.35861469262325957" NO="2" P_CHI2="0.22865707030053073" P_Z="0.008471615983983353" STUDIES="5" TAU2="0.0" TOTAL_1="167" TOTAL_2="161" WEIGHT="10.106783884269227" Z="2.632671824464047">
<NAME>Intralipid</NAME>
<DICH_DATA CI_END="0.8049700679894267" CI_START="0.04969128864618281" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.0942202681398388" LOG_CI_START="-1.3037197405321987" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="28" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Caillot-1994" TOTAL_1="21" TOTAL_2="21" VAR="0.5047619047619047" WEIGHT="3.664046718013446"/>
<DICH_DATA CI_END="0.8714839790766599" CI_START="0.056665087637874714" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.059740592332020795" LOG_CI_START="-1.2466844352186666" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="29" O_E="0.0" SE="0.6972166887783964" STUDY_ID="STD-Moreau-1992" TOTAL_1="16" TOTAL_2="16" VAR="0.48611111111111116" WEIGHT="3.2976420462121014"/>
<DICH_DATA CI_END="14.592576882122193" CI_START="0.05908791195169554" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.16413199010236" LOG_CI_START="-1.2285013568451622" LOG_EFFECT_SIZE="-0.03218468337140124" ORDER="30" O_E="0.0" SE="1.4054446717230549" STUDY_ID="STD-Nath-1999" TOTAL_1="84" TOTAL_2="78" VAR="1.9752747252747254" WEIGHT="0.3799752152013944"/>
<DICH_DATA CI_END="1.9176632412474615" CI_START="0.22829148799116017" EFFECT_SIZE="0.6616541353383458" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2827723435495422" LOG_CI_START="-0.6415102811833765" LOG_EFFECT_SIZE="-0.1793689688169172" ORDER="31" O_E="0.0" SE="0.5429281890408979" STUDY_ID="STD-Nucci-1999" TOTAL_1="19" TOTAL_2="22" VAR="0.29477101845522896" WEIGHT="2.377162017052626"/>
<DICH_DATA CI_END="23.955305629446464" CI_START="0.29684910813118387" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3794017160973315" LOG_CI_START="-0.5274642515527693" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="32" O_E="0.0" SE="1.1201025085364418" STUDY_ID="STD-Sch_x00f6_ffski-1998" TOTAL_1="27" TOTAL_2="24" VAR="1.2546296296296295" WEIGHT="0.387957887789659"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6694598020847519" CI_END="0.5271650760744466" CI_START="0.23479764012124" DF="1" EFFECT_SIZE="0.3518197206192598" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="62" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-0.27805336884376575" LOG_CI_START="-0.6293062723625569" LOG_EFFECT_SIZE="-0.4536798206031613" NO="3" P_CHI2="0.4132403336398591" P_Z="4.127174538868352E-7" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="116" WEIGHT="23.35802956529847" Z="5.062996490488621">
<NAME>ABCD</NAME>
<DICH_DATA CI_END="0.7142802402194175" CI_START="0.07347626557886747" EFFECT_SIZE="0.2290909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.1461313639904924" LOG_CI_START="-1.1338529247628695" LOG_EFFECT_SIZE="-0.639992144376681" ORDER="33" O_E="0.0" SE="0.5801925340982738" STUDY_ID="STD-Sandler-2000" TOTAL_1="25" TOTAL_2="21" VAR="0.3366233766233766" WEIGHT="4.380925423711729"/>
<DICH_DATA CI_END="0.5863312803678613" CI_START="0.24647429565469636" EFFECT_SIZE="0.38015206082432973" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="51" LOG_CI_END="-0.23185693588722153" LOG_CI_START="-0.6082283657879829" LOG_EFFECT_SIZE="-0.4200426508376023" ORDER="34" O_E="0.0" SE="0.22108244099233246" STUDY_ID="STD-White-1998" TOTAL_1="98" TOTAL_2="95" VAR="0.048877445715128164" WEIGHT="18.97710414158674"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6996029943023524" CI_START="0.09219496564334054" DF="0" EFFECT_SIZE="0.25396825396825395" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="-0.15514834040804673" LOG_CI_START="-1.035292793187267" LOG_EFFECT_SIZE="-0.595220566797657" NO="4" P_CHI2="1.0" P_Z="0.008026496407038067" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="56" WEIGHT="6.15559848626259" Z="2.650953193188081">
<NAME>ABLC</NAME>
<DICH_DATA CI_END="0.6996029943023524" CI_START="0.09219496564334054" EFFECT_SIZE="0.25396825396825395" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" LOG_CI_END="-0.15514834040804673" LOG_CI_START="-1.035292793187267" LOG_EFFECT_SIZE="-0.595220566797657" ORDER="35" O_E="0.0" SE="0.5170012083478206" STUDY_ID="STD-Subira-2004" TOTAL_1="49" TOTAL_2="56" VAR="0.2672902494331066" WEIGHT="6.15559848626259"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="20.088933262156957" CI_END="-4.599994472309152" CI_START="-33.96719700965929" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-19.28359574098422" ESTIMABLE="YES" I2="75.11067444572143" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2008-07-10 16:09:05 +0100" MODIFIED_BY="Clare Jess" NO="5" P_CHI2="0.0012026080303249032" P_Q="1.0" P_Z="0.01005389114598133" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="218.55252436970812" TOTALS="YES" TOTAL_1="160" TOTAL_2="143" UNITS="" WEIGHT="100.00000000000001" Z="2.573970271542888">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Lipid-based</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="20.088933262156957" CI_END="-4.599994472309152" CI_START="-33.96719700965929" DF="5" EFFECT_SIZE="-19.28359574098422" ESTIMABLE="YES" I2="75.11067444572143" ID="CMP-001.05.01" MODIFIED="2008-07-10 16:09:05 +0100" MODIFIED_BY="Clare Jess" NO="1" P_CHI2="0.0012026080303249032" P_Z="0.01005389114598133" STUDIES="6" TAU2="218.55252436970812" TOTAL_1="160" TOTAL_2="143" WEIGHT="100.00000000000001" Z="2.573970271542888">
<NAME>Intralipid</NAME>
<CONT_DATA CI_END="-20.633912009885183" CI_START="-50.08608799011482" EFFECT_SIZE="-35.36" ESTIMABLE="YES" MEAN_1="82.21" MEAN_2="117.57" ORDER="36" SD_1="22.98" SD_2="25.64" SE="7.513448260413109" STUDY_ID="STD-Caillot-1994" TOTAL_1="21" TOTAL_2="21" WEIGHT="20.409355712991527"/>
<CONT_DATA CI_END="-0.9910432295763698" CI_START="-59.00895677042363" EFFECT_SIZE="-30.0" ESTIMABLE="YES" MEAN_1="90.0" MEAN_2="120.0" ORDER="37" SD_1="16.0" SD_2="57.0" SE="14.800760115615684" STUDY_ID="STD-Moreau-1992" TOTAL_1="16" TOTAL_2="16" WEIGHT="12.825572487779894"/>
<CONT_DATA CI_END="1.7386559025506942" CI_START="-11.738655902550693" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="49.0" MEAN_2="54.0" ORDER="38" SD_1="16.0" SD_2="20.0" SE="3.4381529230661134" STUDY_ID="STD-Nath-1999" TOTAL_1="67" TOTAL_2="50" WEIGHT="24.36332811061342"/>
<CONT_DATA CI_END="7.573553809167631" CI_START="-25.57355380916763" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="85.0" MEAN_2="94.0" ORDER="39" SD_1="27.0" SD_2="27.0" SE="8.456050182502183" STUDY_ID="STD-Nucci-1999" TOTAL_1="19" TOTAL_2="22" WEIGHT="19.350187157874156"/>
<CONT_DATA CI_END="-12.93828125291914" CI_START="-64.86171874708084" EFFECT_SIZE="-38.89999999999999" ESTIMABLE="YES" MEAN_1="84.9" MEAN_2="123.8" ORDER="40" SD_1="23.9" SD_2="34.4" SE="13.246018269653716" STUDY_ID="STD-Pascual-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="14.24499376194969"/>
<CONT_DATA CI_END="43.30867993657879" CI_START="-36.908679936578814" EFFECT_SIZE="3.1999999999999886" ESTIMABLE="YES" MEAN_1="109.1" MEAN_2="105.9" ORDER="41" SD_1="72.2" SD_2="73.6" SE="20.46398824312638" STUDY_ID="STD-Sch_x00f6_ffski-1998" TOTAL_1="27" TOTAL_2="24" WEIGHT="8.80656276879132"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.768154504541691" CI_END="0.9743411859057446" CI_START="0.6188486606203651" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7765112606298947" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="129" I2="48.50771830476106" I2_Q="58.430126721427015" ID="CMP-001.06" LOG_CI_END="-0.011288939209857515" LOG_CI_START="-0.20841554466880136" LOG_EFFECT_SIZE="-0.10985224193932941" METHOD="MH" MODIFIED="2008-07-10 16:06:41 +0100" MODIFIED_BY="Clare Jess" NO="6" P_CHI2="0.10044999305558988" P_Q="0.0653005845167991" P_Z="0.028929323296539203" Q="7.216764842885238" RANDOM="NO" SCALE="255.91307899195164" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="592" TOTAL_2="607" WEIGHT="100.00000000000001" Z="2.1844482871380717">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Lipid-based</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.07144455953517298" CI_END="1.077099855102128" CI_START="0.5643634316793382" DF="1" EFFECT_SIZE="0.7796638830205969" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="71" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.03225596746658309" LOG_CI_START="-0.2484411344187326" LOG_EFFECT_SIZE="-0.10809258347607477" NO="1" P_CHI2="0.7892450049931117" P_Z="0.1311684480982913" STUDIES="2" TAU2="0.0" TOTAL_1="396" TOTAL_2="399" WEIGHT="55.06074081753749" Z="1.5095102100167355">
<NAME>AmBisome</NAME>
<DICH_DATA CI_END="2.4743386382545527" CI_START="0.3197576353324563" EFFECT_SIZE="0.889487870619946" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.39345913695071444" LOG_CI_START="-0.49517907642503134" LOG_EFFECT_SIZE="-0.050859969737158416" ORDER="42" O_E="0.0" SE="0.5219904853670126" STUDY_ID="STD-Leenders-1998" TOTAL_1="53" TOTAL_2="55" VAR="0.27247406681368946" WEIGHT="5.344766672018207"/>
<DICH_DATA CI_END="1.0795177138243077" CI_START="0.5461740778185075" EFFECT_SIZE="0.7678571428571429" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="64" LOG_CI_END="0.03322977307417038" LOG_CI_START="-0.26266891592739816" LOG_EFFECT_SIZE="-0.11471957142661386" ORDER="43" O_E="0.0" SE="0.17381235464165468" STUDY_ID="STD-Walsh-1999" TOTAL_1="343" TOTAL_2="344" VAR="0.03021073462607634" WEIGHT="49.71597414551928"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5468304500909338" CI_START="0.005342836902022138" DF="0" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.18944271277800082" LOG_CI_START="-2.272228083094451" LOG_EFFECT_SIZE="-1.041392685158225" NO="2" P_CHI2="1.0" P_Z="0.09725728695112247" STUDIES="2" TAU2="0.0" TOTAL_1="49" TOTAL_2="54" WEIGHT="4.278694613448538" Z="1.6582982258195809">
<NAME>Intralipid</NAME>
<DICH_DATA CI_END="1.5468304500909338" CI_START="0.005342836902022138" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.18944271277800082" LOG_CI_START="-2.272228083094451" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="44" O_E="0.0" SE="1.4459976109624424" STUDY_ID="STD-Caillot-1994" TOTAL_1="21" TOTAL_2="21" VAR="2.090909090909091" WEIGHT="4.278694613448538"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="45" O_E="0.0" SE="0.0" STUDY_ID="STD-Nucci-1999" TOTAL_1="28" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3816938993320587" CI_START="0.7237493054600748" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.1404118400313491" LOG_CI_START="-0.14041184003134916" LOG_EFFECT_SIZE="0.0" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="98" WEIGHT="32.67366795724338" Z="0.0">
<NAME>ABCD</NAME>
<DICH_DATA CI_END="1.3816938993320587" CI_START="0.7237493054600748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.1404118400313491" LOG_CI_START="-0.14041184003134916" LOG_EFFECT_SIZE="0.0" ORDER="46" O_E="0.0" SE="0.1649572197684645" STUDY_ID="STD-White-1998" TOTAL_1="98" TOTAL_2="98" VAR="0.0272108843537415" WEIGHT="32.67366795724338"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8920980979368873" CI_START="0.04840006017165023" DF="0" EFFECT_SIZE="0.2077922077922078" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="-0.04958738659900217" LOG_CI_START="-1.315154098434112" LOG_EFFECT_SIZE="-0.682370742516557" NO="4" P_CHI2="1.0" P_Z="0.03455333955278152" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="56" WEIGHT="7.986896611770605" Z="2.1135544526088306">
<NAME>ABLC</NAME>
<DICH_DATA CI_END="0.8920980979368875" CI_START="0.04840006017165023" EFFECT_SIZE="0.2077922077922078" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.04958738659900207" LOG_CI_START="-1.315154098434112" LOG_EFFECT_SIZE="-0.682370742516557" ORDER="47" O_E="0.0" SE="0.7434001511882022" STUDY_ID="STD-Subira-2004" TOTAL_1="49" TOTAL_2="56" VAR="0.5526437847866419" WEIGHT="7.986896611770605"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-09-29 10:19:46 +0100" MODIFIED_BY="Clare Jess">
<APPENDIX ID="APP-01" MODIFIED="2011-09-29 10:19:46 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE MODIFIED="2011-09-29 10:19:46 +0100" MODIFIED_BY="Clare Jess">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-29 10:19:46 +0100" MODIFIED_BY="Clare Jess">
<P>#1: random* OR control* OR blind*<BR/>#2: nystatin OR amphotericin OR fluconazol* OR itraconazol* OR ketoconazol* OR miconazol* OR voriconazol*<BR/>#3: bone-marrow OR cancer* OR fungemia OR hematologic* OR malignan* OR neoplas* OR neutropeni* OR granulocytopeni* OR leukemi* OR lymphom*<BR/>#4: #1 AND #2 AND #3.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>